Process of constructing oxidation-reduction nanomedicine quantum dots room temperature quantum bit networks

ABSTRACT

Preparation of oxidation-reduction (redox) nano-medicine quantum dot room temperature superconductor quantum bit (qubit) networks includes processes of making unitary, binary, ternary, and/or quaternary liquid pharmaceutical ingredients of an antioxidase antioxidant, a β-adrenergic receptor agonist, a P 2 -purinergic receptor agonist, and/or a phenylalkylamine calcium channel blocker in combination with either 1:20 xanthine oxidase (XO):xanthine (X) or X alone in a liquid phase by using the L 16 (2) 15  and L 9 (3) 4  orthogonal optimization design protocols and modulating spatial distance constraint from about 0.1 Å to about 200 Å as well as a  10  class clean bottom-up self-assembly approach. Redox nano-drug quantum dot superconductor qubit network can be identified at room temperature by Planck constant ()-related qubit metrology of electron spins and polaritons (the quantum state of photon-exciton hybrid or photoelectron coupling/co-tunneling) through conducting atomic force microscopy (C-AFM) and/or laser micro- photoluminescence (PL) spectrum standard measurement method, wherein -related quantum continuous variables (QCVs) are derived from faster Fourier transformation (FFT) of average current-voltage (I-V) curves and PL spectra, their first derivatives of relative phases in frequency and time domains (dr/df=ΔE/ and dr/dt=ΔE/) and their FFTs to acquire Σ(2 n ), Σ(2 n ·2 n ), Σ(2 n+1 ), Σ(2 n ·2 n ), Σ(2 2n+1 ·2 2n+1 ) and/or Σ(2 2n+1 ) binary superconductor qubit matrix networks. Uses of this invention cover room temperature superconductor (resistance loss, insulator with conductor or ∞ conductance) quantum devices and quantum biology metrology, implanted nano-drug quantum dot diagnostic and therapeutic nanodevices and/or nano-bio-electrochemistry sensors with target-recognized functions.

TECHNICAL FIELD

This invention relates to preparation processes of turning a hybridsystem of liquid pharmaceutical ingredients and a bio-redox singleelectron tunneling into a redox nano-medicine quantum dot roomtemperature superconductor qubit network and promising broad uses inhigh density and high performance qubit memory devices, nano-drugquantum dot diagnostic and therapeutic new tools and qubit metrology aswell as advanced nano-fabrication.

BACKGROUND

Redox nano-drug quantum dot room temperature superconductor qubitnetworks are the key component for developing high performance quantumcalculation and implanted ultra-fast or ultra-sensitive diagnosticnano-devices and nano-biosensors. It becomes the hot point ofbiochemistry, informatics, nano-technology and advanced functionalsemiconductor nano-particle materials as well as extreme fabricationfields. Single bio-electron tunneling at room temperature is a peculiarproperty of redox nanomedicine quantum dots under the external fieldeffects, for example, employing a serial of electrical pluses, laserand/or photo-electro-magnetic fields. External fields-induced ±½πNsingle electron spin-up and spin-down states at the surface of redoxnanomedicine quantum dots generates one-level and two-level qubitoperators either |0> and |1> or |00> and |11>, which are fundamentalfactors to perform qubit memory, ultra-fast and ultra-sensitivediagnostic techniques and nano-bio-photoelectron sensors. Verapamil,isoproterenal, superoxide dismutase and adenosine triphosphate arepromising to act as building blocks with peculiar bio-photoelectronspins for qubit operators under external fields providing that roomtemperature single electron and single photon co-tunneling interactionsand single electron spins occur in the nanometer spatial structures.Owning to the merit of room temperature single bio-electron and singlephoton co-tunneling interactions and spins is unique, the roomtemperature superconductor qubit network of redox nano-drug quantum dotsmay be achieved by a bottom-up self-assembly approach and superconductorqubit networks may be identified by -related qubit metrology forelectron spins through C-AFM I-V and/or laser micro-PL spectrummeasurement method standard, wherein -related quantum continuousvariables (QCVs) can be acquired from faster Fourier transformation(FFT) of average I-V curves and PL spectra, their first derivatives ofrelative phases in frequency and time domains (dr/df=ΔE/ anddr/dt=ΔE/) and their FFTs providing that qubit operators satisfy thesuperconductor binary code matrix of either Σ(2^(n))n, Σ(2^(n)·2^(n))n,Σ(2^(n+1))n, Σ(2^(2n)·2^(2n))n, Σ(2^(2n+1)·2^(2n+1))n or Σ(2^(2n+1))n.

SUMMARY

In one aspect of the invention, a feature of constructing redoxnanomedicine quantum dot room temperature qubit networks contains aprocess of a droplet-quantum crystal lattice epitaxy bottom-upself-assembly approach to prepare basic building blocks of redoxnanomedicine quantum dot room temperature superconductor qubit networksby turning aromatic structures-, single electrons-, single photons-basedredox pharmaceuticals into molecular mono-layered room temperaturesuperconductor qubit network structures in a liquid phase, includingco-crystallized semiconductor nano-particles (quantum dots), controlledNOT (CNOT) and Majority quantum cellular automates (QCAs),three-particle single electron transistors and qubit central processorunits (QCPU).

The preparation process of the invention may include the followingfeatures.

-   -   i) In a 10 class clean environment, a liquid required for a        redox nanomedicine quantum dot room temperature superconductor        qubit network may be respectively prepared according to the        L₁₆(2)¹⁵ and L₉(3)⁴ orthogonal optimum protocols and safe food        drug agency (SFDA) standards issued by the Ministry of Health in        China.    -   ii) A 3-dimensional (3D) size-controlled redox nano-medicine        quantum dot room temperature superconductor qubit network may be        respectively prepared according to the L₁₆(2)¹⁵ and L₉(₃)⁴        orthogonal optimum protocols in a liquid phase by a bottom-up        self-assembly approach of controlling the intermolecular spatial        distance from about 0.1 Å to about 200 Å.    -   iii) Droplets for a required redox nanodrug quantum dot room        temperature superconductor qubit network may be respectively put        onto substrate surfaces, for example, either a freshly separated        clean highly ordered graphite surface, a 0.01-0.05 Ω·cm n-doped        silicon surface with hydrogen bonding or a 8-12 Ω·cm p-doped        silicon surface with hydrogen bonding, according to the L₁₆(2)¹⁵        and the L₉(3)⁴ orthogonal optimum protocols and national        pharmaceutical manufacture standards. Alternatively, a        0.01-0.050 Ω·cm n-doped silicon surface with hydrogen bonding or        a 8-12 Ω·cm p-doped silicon surface with hydrogen bonding may be        respectively immersed in the desired redox pharmaceutical        hydrochloride and physiological buffer solutions according to        the L₁₆(2)¹⁵ and the L₉(3)⁴ orthogonal optimum protocols. Liquid        redox pharmaceutical samples may be kept at room temperature        (4-18° C.) onto the graphite substrate for 30-60 minutes, liquid        redox pharmaceutical samples may be coated onto the silicon        substrates at either −4-−20° C. critical self-assembly        temperature for a period of either 8-12 or 96 hours, up to        forming either redox nanomedicine quantum dot networks with        electron spins (qubits) in a Σ(2^(n)) and/or a Σ(2^(n+1)) binary        code matrix (superconductor) manner    -   iv) A droplet of hetero-molecular core-shell quantum dot lattice        epitaxy may be respectively made onto the substrate in the        L₁₆(2)¹⁵ and the L₉(3)⁴ orthogonal optimum protocols by a hybrid        redox nanomedicine droplet to form a hetero-molecular core-shell        quantum dot lattice, a three-quantum dot transistor, and a qubit        central processor unit.    -   v) A hybrid redox nanomedicine droplet to form the redox        nanomedicine quantum dot room temperature qubit network        embodiment of a hetero-molecular core-shell quantum dot lattice,        a three-quantum dot transistor, and a qubit central processor        unit as well as a quantum cellular automate (QCA) may be a uni-,        bi-, tri-, tetra-, quin- and/or hexa-hybrid droplet of agonists        of the β-adrenergic receptor and the P₂-purinergic receptor        (isoproterenol hydrochloride and adenosine triphosphate buffer        solutions), antagonists of the Ca²⁺ channel and the super-oxide        anion (verapamil hydrochloride and superoxide dismutase buffer        solutions), and XO: X or X buffer solutions.    -   vi) A redox nanomedicine quantum dot room temperature qubit        network, including a hetero-molecular core-shell quantum dot        lattice, a three-quantum dot transistor, a qubit central        processor unit and/or a QCA, may be made by about single        molecules to about trillion billions of uni-, bi-, tri-, tetra-,        quin- and/or hexa-hybrid molecules selected from 24 groups of        molecular mixture ratios of verapamil hydrochloride        isoproterenol hydrochloride:superoxide dismutase        buffer:adenosine triphosphate buffer with either 1:20 XO:X or X        as follows: (i) 1:0:0:0; (ii) 0:1:0:0; (iii) 0:0:1:0; (iv)        0:0:0:1; (v) 1:1:0:0; (vi) 1:0:1:0; (vii) 1:0:0:1; (viii)        0:1:0:0; (ix) 0:1:0:1; (x) 0:0:1:1; (xi) 1:1:1:0; (xii)        1:0:1:1; (xiii) 1:1:0:1; (xiv) 0:1:1:1; (xv) 1:1:1:1; (xvi)        1:2:2:2; (xvii) 1:3:3:3; (xviii) 2:1:2:3; (xix) 2:2:3:1; (xx)        2:3:1:2; (xxi) 3:1:3:2; (xxii) 3:2:1:3; (xxiii) 3:3:2:1, and        combinations thereof, in an L₁₆(2)¹⁵ and an L₉(3)⁴ orthogonal        design protocols, wherein (xv) may be same a tetra-hybrid        droplet in an L₁₆(2)¹⁵ and an L₉(3)⁴ orthogonal design        protocols.    -   vii) Washing substrate surfaces three times with clean        de-ionized water after 96 hours must be done to secure a        self-assembled monolayer of redox nanomedicine quantum dot        network lattice onto the substrates for some embodiments of        single molecular scale redox nanomedicine room temperature        superconductor qubit networks.

The invention of redox nano-drug quantum dot room temperaturesuperconductor qubit networks may include the following features. Asingle bioelectronics system is coupled with pharmaceutical ingredientsof an agonist of the β-adrenergic receptor, an agonist of theP₂-purinergic receptor, an antioxidase antioxidant, and an antagonist ofthe Ca²⁺ channel in a uni-, a bi-, a tri-, a tetra-, a quinque- or ahexa-complex manner. The β-adrenergic agonist may include isoprenaline.The molecular number of a desired isoprenaline hydrochloride solutionmay be in a range of about single molecule to about 10¹⁵-10¹⁴. TheP₂-purinergic agonist may include adenosine triphosphate. The molecularnumber of a desired adenosine triphosphate physiological buffer solutionmay be in a range of about single molecule to about 10¹¹-10¹⁹. Thephenylalkyl-amine calcium channel blocker may include verapamil. Themolecular number of a desired verapamil hydrochloride solution may be ina range of about single molecule to about 10¹²-10¹⁴. The antioxidaseantioxidant may include superoxide dismutase. The molecular number ofsuperoxide dismutase may be in a range of about single molecule to about10¹¹-10¹³. The single bioelectronics system may be either xanthineoxidase (XO) and xanthine (X) or X. The molecular mixture ratio of XO:Xmay be 1:20. The molecular number of XO may be in a range about singlemolecule to about much more molecules. The molecular number of X may bein a range of about 1-20 single molecules to about 3×10¹⁶-3×10¹⁹.

For the coupled embodiments of single molecular levelpharmaceutical-xanthine droplet hybrids, unitary complexes of a redoxnano-medicine quantum dot room temperature superconductor qubit networkcomposition may comprise a single molecular mixture ratio of(verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate)selected from the group consisting (i) 1:0:0:0; (ii) 0:1:0:0; (iii)0:0:1:0; (iv) 0:0:0:1, and combinations thereof, in an L₁₆(2)¹⁵orthogonal design protocol. Binary complexes of a redox nano-medicinequantum dot room temperature superconductor qubit network compositionmay comprise a single molecular mixture ratio of(verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate)selected from the group consisting of (i) 1:1:0:0; (ii) 1:0:1:0; (iii)1:0:0:1; (iv) 0:1:0:0; (v) 0:1:0:1; (vi) 0:0:1:1, and combinationsthereof, in an L₁₆(2)¹⁵ orthogonal design protocol. Ternary complexes ofa redox nano-medicine quantum dot room temperature superconductor qubitnetwork composition may comprise a single molecular mixture ratio of(verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate)selected from the group consisting of (i) 1:1:1:0; (ii) 1:0:1:1; (iii)1:1:0:1; (iv) 0:1:1:1, and combinations thereof in an L₁₆(2)¹⁵orthogonal design protocol. Quaternary complexes of a redoxnano-medicine quantum dot room temperature superconductor qubit networkcomposition may comprise a single molecular mixture ratio of(verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate)selected from the group consisting of (i) 1:1:1:1; (ii) 1:2:2:2; (iii)1:3:3:3; (iv) 2:1:2:3; (v) 2:2:3:1; (vi) 2:3:1:2; (vii) 3:1:3:2; (viii)3:2:1:3; (ix) 3:3:2:1, and combinations thereof, in an L₉(3)⁴ orthogonaldesign protocol, wherein (i) may be overlapped in an L₁₆(2)¹⁵ orthogonaldesign protocol. All of them are mixed with xanthine at the singlemolecular level.

The feature of a redox nano-medicine quantum dot room temperaturesuperconductor qubit network composition may be identified by eitherC-AFM topographic structure images and I-V curve measurements, lasermicro-PL spectra or both at room temperature and in air, wherein-related QCVs may be acquired from faster Fourier transformation (FFT)of average I-V curves and/or PL spectra, their first derivatives ofrelative phases in frequency and time domains (dr/df=ΔE/ anddr/dt=ΔE/) and their FFTs for characterizing qubit operatorpermutations, angular frequency of electron spins, phase transitions forqubits, velocities and amplitudes of quantum waves and electron-photoncoupling effects in frequency and time domains.

The feature of a redox nano-medicine quantum dot room temperaturesuperconductor qubit network composition may be modulated underdifferent external fields, for example, altering laser sources, photonenergy levels, electron or photon pulses and/or employing spinningmagnetic fields, for instance, toned tuned spinning magnetic fields of70D, 70D150t, 98D, 101D, 104D, 109D, 113D, 117D, RTD10, RTD50t, RTD110t,according to the L₁₆(2)¹⁵ and L₉(3)⁴ orthogonal optimum protocols,thereby, symmetry spin-up and spin-down qubits and non-symmetry spin-upand spin-down qubits may be converted either at about ±10⁻¹⁹ Hz/s toabout ±10⁻⁷ Hz/s in frequency and time domains or at about ±10V biaspotentials. The electron-photon coupling-driven single-level andtwo-level Hadamard and XOR quantum gated room temperature superconductorqubit networks may be acquired within ±5000 nm wavelengths, whereinqubit networks may include qubit operators in a range of about unitaryqubit operators (|10> and |1>) to about several millions of single-leveland two-level qubit operator networks and qubit operator permutations.Energy flips of qubit networks in frequency and time domains may be in arange of about 5.441E-36 eV to about 109339.95665 eV. Angular momentumof phase transitions in frequency and time domains may be in a range ofabout 10⁻¹⁹ Hz to about 10⁵ Hz. Phase transitions may undergo ±½πN PauliZ magnetic momentum.

The feature of redox nano-drug quantum dot room temperaturesuperconductor qubit networks may satisfy the trillion level binary codematrix Hamiltonians of superconductor qubit networks as follows.Σ{(2^(n)), n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 . . . };Σ{(2^(n)·2^(n)), n=1, 2, 3, 4, 5, 6 . . . }; Σ{(2^(n+1)), n=1, 2, 3, 4,5, 6, 7, 8, 9, 10, 11 . . . }; Σ{(2^(2n)·2^(2n)), n=1, 2, 3 . . . };Σ{(2^(2n+1)·2^(2n+1)), n=1, 2, . . . }; Σ(2^(2n+1)), n=1, 2, 3, 4, 5, .. . }.

The feature of redox nano-drug quantum dot room temperaturesuperconductor qubit networks may be single electron spins- and/orsingle photoelectron co-tunneling-driven quantum circuit-gated roomtemperature superconductor qubit networks, wherein single bio-electronspins may confer a feature of ±½πN phase transitions for one-level andtwo-level qubit operator networks and their permutations at roomtemperature.

The bi-stable spin-down and spin-up quantum resonance transport featureof redox nano-drug quantum dot room temperature superconductor qubitnetworks may conclude the weak spin-orbital and hyperfine hybrid ofmolecular scale quantum and/or magnetic tunnel junctions (QTJs and/orMTJs) to be acted as promising ultra-thin and/or ultra-small spintronicdevices.

The embodiment feature of redox nano-drug quantum dot room temperaturesuperconductor qubit networks may be atomic scale CNOT- andMajority-gated QCA architectures that may be identified by C-AFM imagesand laser-micro-PL spectra as well as -related QCVs, especially theforward and backward FFTs of dr/df=ΔE/ and dr/dt=ΔE/.

The double-peaked PL spectra of redox nano-drug quantum dot roomtemperature superconductor qubit networks may directly confer theband-gap structure feature of bonding and anti-bonding energy statesbetween two coupled redox nano-drug quantum dots and/or electrostaticquantum dot networks.

The double-oriented electron-hysteresis-like peaks within an averagedifference conductance spectrum may confer the superconductor band-gapstructure feature of bonding and anti-bonding energy states between twocoupled redox nano-drug quantum dots and/or electrostatic quantum dotnetworks

The band-gap structure dynamic feature of redox nano-drug quantum dotroom temperature superconductor qubit networks may be identified byqubit metrology (-related measurement method standard of qubits), whichmay comprise QCVs, namely, double-peaked average I-V curves,double-peaked average differential conductance spectra and double-peakedaverage laser micro-PL spectra, their FFTs, the 1^(st) derivative ofrelative phases in frequency and time domains (dr/df & dr/dt), and dr/df& dr/dt FFTs, wherein either dr/df or dr/dt equal to ΔE/.

The -related measurement method standard of qubits may comprise theprior calibration of C-AFM tip and/or laser-micro-PL spectrum systemtool, as well as standard samples as the background signal to acquireQCVs of redox nano-drug quantum dot room temperature superconductorqubit networks in comparison with the background signal for finalstatistical significance (P value) tests.

Strategic utility of embodiments in the invention covers nationaldefense, and international information security, as well asnanotechnology and nanoscience.

Industry utility of embodiments in the invention coversbio-photoelectron sensors, advanced information materials, singlebioelectronics transistors, implanting nano-bio-photoelectron sensors,newly medical diagnostic tools like room temperature superconductivitynuclear magnetic imaging, cardio-cerebral magnetic probing, highperformance single bioelectronics and single bio-photonco-tunneling-driven room temperature superconductivity qubit informaticsand nanometer photoelectron biosensors, and key technology employed incommunication, traffic and national defense advanced tools like quantumcomputers, superconductivity magnetic body and energy storage systems.

Standard utility of embodiments in the invention covers standardreference samples and nano-metrology of qubits and QCAs as well as qubitcircuits.

The details of one or more embodiments of the invention are set forth inthe accompanying drawings and the description below. Other features,objects, and advantages of the invention will be apparent from thedescription and drawings, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1. A, C-AFM characterizes quantum tunneling current spectrum ofredox nanomedicine quantum dot room temperature qubit networks onto the0.01-0.05 Ω·cm n-doped silicon chip, wherein the quantum resonanceswitching-on is about at 0.01 nA and the quantum resonance switching-offis about at −0.07 nA toward quantum standard and the area of quantumtunneling current spectrum is 5000 Å×5000 Å. B, C-AFM characterizes thebi-stable quantum tunneling current at the maximum value about 45 pA andthe minimum value about −45 pA and single electron spin hysteresis I-Vcurve of FIG. 1 a within ±6V bias potentials for symmetry spin-up andspin-down qubit operator processing. C, The 1 ^(st) derivative of 1 bcorresponds to bi-stable spin-up and spin-down transports as well asquantum resonance tunneling peaks at ±2V bias potential for qubit memoryin the dI/dV conductance spectrum, revealing the weak spin-orbital andhyperfine hybrid of molecular scale quantum and/or magnetic tunneljunctions (QTJs and/or MTJs) to be used as promising ultra thin/smallspintronic devices. D, The double-peaked laser micro-PL spectrum ofsymmetry photoelectron coupling and 70D magnetic field-toned redoxnanomedicine quantum dot room temperature superconductor qubit networksin energy-frequency-phase and energy-time-phase spectra, wherein dataare profiled as an average PL spectra of 23 measurements with s.d. ontothe n-doped silicon chip, and -related photoelectron coupling- and/orco-tunneling-driven ±2364 qubit networks meet the binary code matrix ofroom temperature superconductor qubit network Hamiltonians as follow.H=Σ{(2^(n)), n=. . . 3, 4 . . . } (1) for 2 one-level symmetry spin-downand spin-up ±½πN Hadamard and/or Pauli Z-gated qubit operator networksand one two-level symmetry spin-down and spin-up XOR-gated qubitoperators with an initially unitary qubit operator |1>, 16 operatorcarries for 1 two-level qubit permutations and 8 operator carries for 2one-level qubit operator network permutations in a sum of ±2 and double(±8, ±16) operators in a sum of ±2364 spin-down and spin-up phasetransition degrees with ±½πN angular momentum. FIG. 1 a-d extended FIG.2 in the PCT/CN/2005/002368 application. The preparation process of asample in FIG. 1 a-d follows up the desired 0:1:0:0 molar ratio in theL₁₆(2)¹⁵ orthogonal design protocol.

FIG. 2. A, C-AFM characterizes topographic structure of a self-assembledredox nanomedicine quantum dot room temperature superconductor qubitnetwork onto the 0.01-0.05 Ω·cm n-doped silicon chip, according to amolar ratio of 1:1:1:1 in the L₁₆(2)¹⁵ orthogonal design model, whereinits 3D hexahedral size is stacked as a length 9000 Å, a width 9000 Å anda height 85 Å. B, The average double-peaked PL spectrum of FIG. 2 areveals an optical quantum property, wherein photon-electron-magneticexternal field-toned symmetry and atomic scale non-symmetryphotoelectron coupling effects are profiled in the average lasermicro-PL spectra of 99 optical quantum feature measurements with s.d.under toned spinning magnetic fields of respectively using either 70D,70D150t, 98D, 101D, 104D, 109D, 113D, 117D, RTD10t, RTD50t or RTD110t.Statistical significance P<0.01 are showed by error bars thereof. C, Aparadigm of spinning magnetic field-toned redox nano-medicine quantumdot room temperature superconductor qubit networks associatenon-symmetry spin-down QCVs in the -related energy-frequency-phasespectrum that corresponds to FIG. 2 b. D, A paradigm of spinningmagnetic field-toned redox nano-medicine quantum dot room temperaturesuperconductor qubit networks associate non-symmetry spin-up QCVs in the-related energy-time-phase spectrum that corresponds to FIG. 2 b. C andD, The average room temperature qubit operators of FIG. 2 b are achievedat symmetry spin-down and spin-up ±4302 phase transition degrees,wherein spin-down and spin-up qubit operator networks satisfy the binarycode matrix of room temperature superconductor qubit operator networkHamiltonian as follows. H=Σ{(2^(n+1)), n=0, 1, 2, 3, 4} (1) for 3one-level symmetry spin-down and spin-up ±½πN Hadamard and/or PauliZ-gated qubit operator networks and 2 two-level symmetry spin-down andspin-up XOR-gated qubit operator networks with an initially unitaryqubit operator |0>, carries 64 operators for 4 two-level XOR-gated qubitoperator permutations and carries 8 operators for 2 one-level Hadamardand/or Pauli Z-gated qubit operator permutations with ±½πN angularmomentum. The following binary code matrix Hamiltonians respectivelycorrespond to 11 different types of symmetry and non-symmetry qubitoperator networks within a range of about 0 Hz/s-10⁻¹⁹ Hz/sfrequency/time domains and an energy flipping range of 5.441E-36eV-631,00065 eV as profiled in FIG. 2 b. [1] H=Σ{(2^(n)), n=. . . 3, 4 .. . } for 2 one-level symmetry spin-down and spin-up ±½πN Hadamardand/or Pauli Z-gated qubit operator networks and 1 two-level symmetryspin-down and spin-up XOR-gated qubit operators with initial unitaryqubit operators |0> and |1>, and 1 spin-down and spin-up qubit operatorcarry |0> in a sum of ±1, ±2, ±8, ±16 qubit operators with ±1 carry with±½πN angular momentum, which corresponds to the 70D toned PL spectrumwith phase transition degrees of (0, ±2440). [2] H=Σ{2^(n)), n=. . . ,3,4 . . . } for 2 one-level symmetry spin-down ±½πN Hadamard and/orPauli Z-gated qubit operator networks and 1 two-level symmetry spin-downXOR-gated qubit operators with initial unitary qubit operators |0>, and4 carries for 1 one-level qubit operator permutations with ½πN angularmomentum; and 2 one-level symmetry spin-up −½πN Hadamard and/or PauliZ-gated qubit operator networks and 1 two-level symmetry spin-upXOR-gated qubit operators with initial unitary qubit operators |0>, andspin echo (π) for qubit networks, which corresponds to 70D150t toned PLspectrum with phase transition degrees of (180, +2254, −2250) with −½πNangular momentum. [3] H=Σ{(2^(n)), n=. . 3, 4, . . . } for 2 one-levelsymmetry spin-down and spin-up ±½πN Hadamard and/or Pauli Z-gated qubitoperator networks and 1 two-level symmetry spin-down and spin-upXOR-gated qubit operators with an initial qubit operator |1>, and 6carries for permutations of one-level and/or two-level qubit operatorswith ±½πN angular momentum, which corresponds to 98D toned PL spectrumwith phase transition degrees of (0, ±2400). [4] H=Σ{(2^(n)), n=1, 2, 3,4, . . . 9} for 3 one-level spin-down ±½πN Hadamard and/or Pauli Z-gatedqubit operator networks and 17 two-level spin-down XOR-gated qubitoperator networks with a unitary qubit |1>, and 7 carries forpermutations of one-level and/or one-level qubit operators in a sum of48787 phase transition degrees with ½πN angular momentum; for 17two-level spin-down XOR-gate qubit operator networks with a unitaryqubit |1>, and 18 carries for permutations of one-level and/or two-levelqubit operations in a sum of 21798 phase transition degrees;H=Σ{(2^(n)), n=1, 2, . . . 5, 6 , . . . 12} for 1 one-level spin-down±e,fra 1/2πN Hadamard and/or Pauli Z-gated qubit operators and 262two-level XOR-gate qubit operator networks with a unitary qubit |1>, and1 carry, as well as double spin echo (π) at initial and end of spin-downqubit operators in a sum of (180, 48787, 21798, 387173, 180) operatorswith ½πN angular momentum; H=Σ{(2^(n)), n=1, . . . 3, 4, . . . 9} for 2one-level spin-up ½πN Hadamard and/or Pauli Z-gated qubit operatornetworks and 33 two-level spin-up XOR-gated qubit operator networks witha unitary qubit |1>, and 7 carries for permutations of one-level and/ortwo-level qubit operators in a sum of −48427 phase transition degreeswith −½πN angular momentum; H=Σ{(2^(n)), n=1, . . . 4, 5, 6, . . . 8, .. . 11} for 151 two-level spin-up XOR-gated qubit operator networks witha unitary qubit |1> in a sum of 217620 phase transition degrees;H=Σ{(2^(n)), n=1, 2, . . . 7, . . . 11} for 1 one-level spin-up −½πNHadamard and/or Pauli Z-gated qubit operators and 264 two-level spin-upXOR-gated qubit operator networks with unitary qubit operators |1> and|0>, and 23 carries for permutations of two-level and/or one-level qubitoperators in a sum of −380813 phase transition degrees, as well asdouble spin echo (π) at spin-up initial and end qubit operators with−½πN angular momentum, which corresponds to 101D toned PL spectrum witha total sum of (180, −48427, −217620, −380813, 180) phase transitiondegrees. [5] H=Σ{(2^(n)), n=. . . 3, 4} for 2 one-level spin-down ½πNHadamard and/or Pauli Z-gated qubit operator networks and 1 two-levelspin-down XOR-gated qubit operators with unitary qubit operators |1> and|0>, and 44 carries for permutations of 2 two-level and 2 one-levelspin-down qubit operations plus double spin echo (π) at initial and endspin-down qubit operators in a sum of (180, 2474, 180) phase transitiondegrees with ½πN angular momentum; H=Σ{(2^(n)), n=1} for a unitary qubitoperator |1 >with 67 carries for permutations of 8 two-level and/orone-level spin-up qubit operators, and double spin echo (π) at initialand end spin-up qubit operators in a sum of (180, −247, 180) phasetransition degrees; all of the non-symmetry spin-down and spin-up qubitsand quaternary spin echo corresponds to 104D toned PL spectrum with atotal sum of (180, 2474, 180, 180, −247, 180) phase transition degrees.[6] H=Σ{(2^(n)), n=. . . 3, 4, . . . 11} for 2 one-level symmetryspin-down and spin-up ±½πN Hadamard and/or Pauli Z-gated qubit operatornetworks and 257 two-level symmetry spin-down and spin-up XOR-gatedqubit operator networks with ±½πN angular momentum, which corresponds to109D toned PL spectrum with a sum of (0, ±186480) phase transitiondegrees. [7] H=Σ{(2^(n)), n=. . . 3, . . . 5, 6, . . . 8} for 2one-level symmetry spin-down and spin-up ±½πN Hadamard and/or PauliZ-gated qubit operator networks and 42 two-level symmetry spin-down andspin-up XOR-gated qubit operator networks with ± 1/eπN angular momentum,which corresponds to 113D toned PL spectrum with a sum of (0, ±32400)phase transition degrees. [8] H=Σ{(2^(n)), n=1, 2, 3, . . . 5, 6, . . .10} for 3 one-level spin-down ½πN Hadamard and/or Pauli Z-gated qubitoperator networks and 70 two-level spin-down XOR-gated qubit operatornetworks with a unitary qubit operator |1>, and double spin echo (π) atan initial and end of spin-down qubit operations with ½πN angularmomentum; and H=Σ{(2^(n)), n=1, . . . 3, . . . 5, 6, . . . 10} for 2one-level spin-up −½πN Hadamard and/or Pauli Z-gated qubit operatornetworks and 70 two-level spin-down XOR-gated qubit operator networkswith a unitary qubit operator |1>, and double spin echo (π) at aninitial and end of spin-up qubit operations with −½πN angular momentum,all of them corresponds to 117D toned PL spectrum with the non-symmetryspin-down and spin-up qubit operator networks in a sum of (180, 102060,180, 180, −101700, 180) phase transition degrees. [9] H=Σ{(2^(n)), n=. .. 2, 3, 4, 5, . . . 7} for 3 one-level symmetry spin-down and spin-up±½πN Hadamard and/or Pauli Z-gated qubit operator networks and 11two-level symmetry spin-down and spin-up XOR-gated qubit operatornetworks with ±½πN angular momentum, which corresponds to RTD10t tonedPL spectrum with a sum of (0, ±16965) phase transition degrees. [10]H=Σ{(2^(n)), n=1, . . . 3, 4, . . . 6, . . . 11} for 2 one-levelspin-down ±½πN Hadamard and/or Pauli Z-gated qubit operator networks and133 two-level spin-down XOR-gated qubit operator networks with a unitaryqubit operator |1>, and double spin echo (π) at an initial and end ofspin-down qubit operators with ½πN angular momentum; and H=Σ{(2^(n)),n=. . . 2, . . . 4, . . . 6, . . . 11} for 1 one-level spin-up −½πNHadamard and/or Pauli Z-gated qubit operators and 137 two-level spin-upXOR-gated qubit operator networks with a unitary qubit operator |1>, anddouble spin echo (π) at an initial and end of spin-up qubit operators,all of them corresponds to RTD50t toned PL spectrum with a sum of (180,192420, 180, 180, −192060, 180) phase transition degrees for thenon-symmetry spin-down and spin-up qubit operators and quaternary spinechoes for networks with −½πN angular momentum; [11] H=Σ{(2^(n)), n=. .. 3, . . . 6, 7, . . . 11} for 2 one-level symmetry spin-down andspin-up ±½πN Hadamard and/or Pauli Z-gated qubit operator networks and140 two-level symmetry spin-down and spin-up XOR-gated qubit operatornetworks with ±½πN angular momentum, which corresponds to RTD110t tonedPL spectrum with a sum of (0, ±202320) phase transition degrees.

FIG. 3. A, C-AFM characterizes topographic structure of self-assembledsingle molecular level redox nano-medicine quantum dot room temperaturesuperconductor qubit network onto the 0.01-0.05 Ω·cm n-doped siliconchip, according to a molecular mixture ratio of 1:1:1:1 in the L₉(3)⁴orthogonal design model, wherein its 3D cross-bar architecture size isstacked as a length 9500 Å, a width 9500 Å and a height 70 Å. B, 70Dspinning magnetic field-toned symmetry single electron and single photoncoupling effect of self-assembled single molecular level redoxnano-medicine quantum dot room temperature superconductor qubit networkonto the 0.01-0.05 Ω·cm n-doped silicon chip, wherein data are profiledas an average double-peaked PL spectra of 14 measurements with s.d. Cand D, Single molecular level redox nano-medicine quantum dot roomtemperature superconductor qubit networks onto the 0.01-0.05 Ω·cmn-doped silicon chip of FIG. 3 b, wherein a -related non-symmetryspin-up (−1884) and spin-down (+2, +2224, +2230, +2439, +2) QCVsassociate with dynamics of power, frequency, time and phase transitions.The spin-up (−1884) phase transition degrees satisfy the roomtemperature superconductor qubit operator network Hamiltonian as follow.H=Σ{(2²·2^(n)), n=1, 2} for 1 one-level spin-up −½πN Hadamard and/orPauli Z-gated qubit operators and 1 two-level spin-up XOR-gated qubitoperators with −½πN angular momentum. The spin-down (+2, +2224, +2230,+2439, +2) phase transition degrees satisfy the room temperaturesuperconductor qubit operator network Hamiltonian as follow. H={(2^(n),n=1} (1) for a unitary qubit operator |1> in a sum of 2 phase transitiondegrees. H=Σ{(219 2^(n)), n=1, 2} (2) for 1 one-level spin-down ½πNHadamard and/or Pauli Z-gated qubit operators and 1 two-level spin-downXOR-gated qubit operators with unitary qubit operators |1> and |0>, and64 carries for permutations of two-level and/or one-level spin-downqubit operators in a sum of 2224 phase transition degrees with ½πNangular momentum. H=Σ{(2^(n)), n=. . . 3, 4} (3) for 2 one-levelspin-down ½πN Hadamard and/or Pauli Z-gated qubit operator networks and1 two-level spin-down XOR-gated qubit operators with 7 carries forpermutations of one-level and/or two-level qubit operators in a sum of2230 phase transition degrees with ½πN phase transition degrees.H=Σ{(2^(n)), n=. . . 3, 4} (4) for 2 one-level spin-down ½πN Hadamardand/or Pauli Z-gated qubit operator networks and 1 two-level spin-downXOR-gated qubit operators with unitary qubit operators |1> and |0>, and9 carries for permutations of one-level and/or two-level qubit operatorswith ½πN phase transition degrees.

FIG. 4. A, B and C, Single molecular level Redox nano-medicinecore-shell quantum dots are respectively C-AFM images for topographicstructures of size-controllable core-shell quantum dot structure at adiameter of 2.6 nm, the 2.6 nm three quantum dot particle transistor,and the 2.6 nm room temperature superconductivity qubit centralprocessor unit (CPU) architecture onto the 0.01-0.05 Ω·cm n-dopedsilicon chip, according to the molecular mixture ratio of 1:3:3:3 in theL₉(3)⁴ orthogonal design model. D, The C-AFM probes an average I-V curveof 6 measurements with s.d. of FIG. 4 a, wherein around 0.05 pA singleelectron spin-up and spin-down current transports in an electron spin-upand spin-down tunneling transport hysteresis loop are clearly visiblewithin ±0.25V bias potentials for memory of qubits. E and F, The-related symmetry spin-up and spin-down QCVs associate with dynamics ofpower, frequency, time and phase in one- and two-level qubit couplings,wherein the qubit operator networks of ±34200 phase transition degreessatisfy the room temperature superconductor qubit operator networkHamiltonian as follows. {H=Σ{(2^(n)), n=1, . . . 4, 5, 6, . . . 8} for23 two-level symmetry spin-down and spin-up XOR-gated qubit operatornetworks with a unitary qubit operator |1> in a sum of ±34200 phasetransition degrees with ±½πN symmetry spin-down and spin-up qubitoperator networks.

FIG. 5. A, C-AFM characterizes the topographic structure ofhexa-ingredient redox nano-medicine quantum dot room temperaturesuperconductivity network onto the graphic substrate according to themolar ratio of 1:1:1:1 in the L₁₆(2)¹⁵ orthogonal design protocol plusthe molar ratio of 1:20 bio-redox single electron system (XO:X) at roomtemperature and in air, wherein the cross-bar hexahedral stacked size ofmolecular scale quantum dot networks is a length 8000 Å, a width 8000 Åand a height 200 Å. B, C-AFM characterizes an average I-V curve of 5measurements plus s.d. that corresponds to FIG. 5 a, wherein thebi-stable quantum tunneling currents of the maximum value at about 0.65pA that results from bio-redox single electron spin-up tunnelingtransport into the upper layer of stacked redox nanomedicine quantumdots and the minimum value at about −065 pA that results from tunnelingof bio-redox single electron tunneling transport into the lower layer ofstacked redox nanomedicine quantum dots within ±10V bias potentials andan electron spin-up and spin-down hysteresis loop of the singlebio-redox electron spin transport with a spin-up current about 0.1 pAand a spin-down current about −0.05 A within ±7.5V bias potentials areclearly shown for memory of qubits. C, The room temperature bi-stablespin-up and spin-down quantum resonance superconductivity properties ofFIG. 5 b are visible by a feature of superconductivity (insulator plusconductor property) with 9 spin-down and spin-up quantum resonancetunneling peaks of about 0.05 pA/V-0.2 pA/V within 0V-10V biaspotentials to about 0.45 pA-0.7 pA/V within ±10V bias potentials for 9spin-down and spin-up superconductor qubit memories at room temperature.D, The spin-down room temperature superconductivity qubit networks ofFIG. 5 c associate with -related amplitudes and angular velocities ofquantum waves in frequency domain. E, The spin-up room temperaturesuperconductivity qubit networks of FIG. 5 c associate with -relatedamplitudes and angular velocities of quantum waves in time domain. F,The spin-down room temperature superconductivity qubit networks of FIG.5 d associate with -related QCVs in power-frequency-phase spectrum. G,The spin-up room temperature superconductivity qubit networks of FIG. 5e associate with -related QCVs in power-time-phase spectrum. H, Thespin-down room temperature superconductivity qubit networks of FIG. 5 fassociate with -related phase transitions in frequency domain. I, Thespin-up room temperature superconductivity qubit networks of FIG. 5 gamplitudes associate with -related phase transitions in time domain.FIG. 5 e, FIG. 5 g, FIG. 5 h and FIG. 5 i reveal single-level andtwo-level symmetry spin-down and spin-up room temperature superconductorqubit operator networks and operator permutations at 9 differentfrequency and time domains in a range of about 0.1 nHz and about 0.5pico seconds with about 10⁻¹⁶ eV-10⁻¹⁷ eV power fluctuations. All aboveoperators satisfy a binary code matrix of redox nano-medicine quantumdot room temperature superconductor qubit network Hamiltonians asfollows. [1] H={(2^(n)·2^(n)), n=1, 2 for 1 one-level symmetry spin-downand spin-up ±½πN Hadamard and/or Pauli Z-gated qubit operators and 1two-level symmetry spin-down and spin-up XOR-gated qubit operators in asum of (±4, ±16) operators with ±½πN phase transition degrees. [2]H=Σ{(2^(n)), n=5, 6} for 6 two-level symmetry spin-down and spin-upXOR-gated qubit operator networks in a sum of (±32, ±64) operators with±½πN phase transition degrees. [3-4] H={(2^(n)·2^(n)), n=1, 2} for 2one-level symmetry spin-down and spin-up ±½πN Hadamard and/or PauliZ-gated qubit operator networks and 2 two-level symmetry spin-down andspin-up XOR-gated qubit operator networks in a sum of double (±4, ±16)operators at two discrete frequency and time domains respectively with±½πN phase transition degrees. [5] H=Σ{(2^(n)), n=7 for 8 two-levelsymmetry spin-down and spin-up XOR-gated qubit operator networks in asum of (±128) operators with ±½πN phase transition degrees. [6-7]H=Σ{(2^(2n+1)), n=1, 2, 3 for 4 one-level symmetry spin-down and spin-up±½πN Hadamard and/or Pauli Z-gated qubit operator networks and 20two-level symmetry spin-down and spin-up XOR-gated qubit operatornetworks in a sum of double (±8, ±32, ±128) operators at two discretefrequency and time domains respectively with ±½πN phase transitiondegrees. [8] H=Σ{(2^(2n+1)), n=1, 2, 3 for 2 one-level one-levelsymmetry spin-down and spin-up ±½πN Hadamard and/or Pauli Z-gated qubitoperator networks and 10 two-level symmetry spin-down and spin-upXOR-gated qubit operator networks in a sum of (±8, ±32, ±128) operatorswith ±½πN phase transition degrees. [9] H={(2^(n)), n=6, 7 for 12two-level symmetry spin-down and spin-up XOR-gated qubit operatornetworks in a sum of (±64, ±128) operators with ±½πN phase transitiondegrees. Owning to ±½ N and ±½πN phase transitions in [1-4] and [6-9]equations, bio-redox single electron spins can achieve room temperaturesingle-level symmetry spin-down and spin-up and two-level symmetryspin-down and spin-up superconductor qubit operator networks and theirpermutations.

FIG. 6. a, C-AFM characterizes the quantum cellular automate (QCA)topographic structure of hexa-ingredient redox nano-medicine quantum dotroom temperature superconductivity network onto the 0.01-0.05 Ω·cmn-doped silicon chip substrate according to the molar ratio of 2:3:1:2in the L₉(3)⁴ orthogonal design model plus the molar ratio of 1:20bio-redox single electron system (XO:X) made at −18° C.-−20° C. for 8-12hours, wherein hexa-ingredient redox nano-medicine quantum dots andquantum wires are regularly stacked in a cubic box of about 200 Å QCAarrays with cross-bar molecular junctions and upper planes and lowerplanes as well as molecular numbers in a range of about 10¹⁹ to about10²², its size of QCA arrays (a typically smaller selected region of QCAarrays are shown in a red line box) is a length of 800 nm, a width of800 nm and an a height of an atomic layer (−0.33 nm) after deducing theheight of a substrate about 0.67 nm (white vs. black). b, C-AFM probesthe I-V curves of FIG. 6 a (data are expressed as an average curve of 6measurements with s.d.), wherein spin-down and spin-up quantum tunnelingcurrents may achieve the maximum of 10 pA and the minimum of −25 pAwithin ±5V bias potentials and there are two electron hysteresis loopswithin 1.5V-2V bias potentials and 0V-−1.5V bias potentials. c, Theaverage dI-dV differential conductance spectra of FIG. 6 b, wherein roomtemperature spin-up and spin-down superconductor quantum resonancetunneling peaks and kondo peaks around 0V bias voltage are clearlyrevealed for room temperature superconductor qubit memory. d, -relatedamplitude and angular momentum of quantum wave of FIG. 6 c in frequencydomains, wherein the amplitudes of double-peaked quantum waverespectively locate 7.5E-7 and 9.5E-4 within 0Hz-5E+4 Hz. e, -relatedamplitude and angular momentum of quantum wave of FIG. 6 c in timedomains, wherein the amplitudes of double-peaked quantum waverespectively locate 3.5E-5 and 4.75E-5 within 0s-5E+4s, revealing afeature of non-volatile qubits. f, Single electron tunneling-driven 11two-level and 3 one-level room temperature spin-down superconductorqubit operator network around 0 Hz with a unitary qubit operator |1> anddouble spin echo, wherein the -related non-symmetry spin-down qubitoperators satisfy the binary code matrix of Hamiltonian H={Σ(2^(n)),n=1, 2, 3, 4, 5, 7} in frequency domains. g, Single electrontunneling-driven 11 two-level and 2 one-level room temperaturenon-symmetry spin-up superconductor qubit operator network around 0swith a unitary qubit operator |1> and double spin echo, wherein the-related spin-up qubit operators satisfy the binary code matrix ofHamiltonian H={Σ(2^(n)), n=1, 3, 4, 5, 7} in time domains. h, Theaverage laser micro-PL spectrum of 6 measurements with s.d. for the FIG.6 a, wherein doubled PL peaks are respectively revealed around 550 nmand 575 nm wavelength with fluorescence intensity from about 4500 a.u.to about 1750 a.u. after smooth processing, suggesting photoelectroncouplings to form polaritons (quantum states obtained from laser-evokeda hybrid photon-exciton pairs) within about 2500 QCA architectures. i,-related amplitude and angular momentum of quantum wave of FIG. 6 h infrequency domains, wherein the amplitude of polaritons is around 1.8E-7within 0 Hz-1.6E-7 Hz. j, -related amplitude and angular momentum ofquantum wave of FIG. 6 h in time domains, wherein the amplitude ofpolaritons is around 9.0E-8 within 0s-1.6E-7s. k, Polaritons-driven 180two-level and 87 one-level symmetry spin-down qubit operator networkswith 120 unitary |0> and/or |1> qubit operators in frequency domains,suggesting 3348 spin-down qubit operators to lay out 36 two-levelqubit-based Majority QCA and 17 one-level spin-down qubitoperators-based Majority QCA with a |1> carry. 1, Polaritons-driven 180two-level and 87 one-level symmetry spin-up qubit operator networks with120 unitary |0> and/or |1> qubit operators, indicating 3348 spin-upqubit operator to lay out 36 two-level spin-up qubit operators-basedMajority QCA and 17 one-level qubit-based Majority QCA with a |1> carry.m, The average laser micro-PL spectrum of 2 measurements with s.d. forthe FIG. 6 a after adding an external spinning magnetic field of RTD10T,wherein doubled PL peaks are respectively revealed around 550 nm and 575nm wavelength with fluorescence intensity from about 3000 a.u. and 1750a.u. after smooth processing, suggesting RTD10T-tuned photoelectroncouplings to form polaritons (quantum states obtained from laser-evokeda hybrid photon-exciton pairs) within about 2500 QCA architectures, anda reduced fluorescent intensity about 1000 a.u. n, -related amplitudeand angular momentum of quantum wave of FIG. 6 m in frequency domains,wherein the RTD10T tuned amplitude of polaritons is around 1.0E-7 within0Hz-1.6E-7 Hz. o, RTD10T tuned polaritons-driven non-symmetry 180two-level spin-up and 37 one-level spin-up qubit operator networks with66 unitary spin-up |0> and/or |1> qubit operators, and 1 two-levelspin-down and 8 one-level spin-down qubit operator network with 23unitary spin-down |0> and/or |1> qubit operators, as well as double spinecho in frequency domains, suggesting 2888 two-level spin-up qubitoperators to lay out 240 controlled NOT(CNOT) QCAs and 148 one-levelspin-up qubit operators to lay out 24 CNOT QCAs, and 16 two-levelspin-down qubit operators to lay out 1 CNOT QCA with 4 carries for 4carries and 32 one-level spin-down qubit operators to lay out 2 CNOTQCAs with 8 carries for permutations of one-level and two-level qubitoperators, as well as 66 spin-up unitary qubit operators and 23spin-down unitary qubit operators and double spin echo for one-level andtwo-level qubit operator networks and qubit operator permutations infrequency domains. p, -related amplitude and angular momentum ofquantum wave of FIG. 6 m in time domains, wherein the RTD10T tunedamplitude of polaritons is around 5.0E-8 within 0s-1.6E-7s. q, RTD10Ttuned polaritons-driven non-symmetry 3 one-level spin-up qubit operatornetworks and 1 two-level spin-up qubit operators with 14 unitary spin-upqubit operators, and 202 two-level spin-down qubit operator networks and41 one-level spin-down qubit operator networks with 91 unitary spin-downqubit operators, suggesting 12 one-level spin-up qubit operator networksto be built as 1 CNOT QCA and 16 two-level spin-up qubit operators to beconstructed as 1 CNOT QCA with 4 carries for permutations of one-leveland two-level qubit operator networks, and 3232 two-level spin-downqubit operator networks to generate 269 CNOT QCAs with 4 carries forpermutations of one-level and two-level qubit operators and 164one-level spin-down qubit operator networks to form 13 CNOT QCAs with 8carries for permutations of one-level and two-level qubit operators. r,The average laser micro-PL spectrum of 9 measurements with s.d. for theFIG. 6 a after adding an external spinning magnetic field of RTD50T,wherein doubled PL peaks are respectively revealed around 550 nm and 575nm wavelength with fluorescence intensity from about 4750 a.u. and 3250a.u. after smooth processing, suggesting RTD50T-tuned photoelectroncouplings to form polaritons (quantum states obtained from laser-evokeda hybrid photon-exciton pairs) within about 2500 QCA architectures, anda rise of fluorescent intensity from about 250 a.u. at 550 nm to about1500 a.u. at 575 nm. s, -related amplitude and angular momentum ofquantum wave of FIG. 6 m in frequency domains, wherein the RTD50T tunedamplitude of polaritons is around 4.0E-7 within 0 Hz-1.6E-7 Hz. t,RTD50T tuned polaritons-driven symmetry 615 two-level and 237 one-levelspin-down qubit operator networks with 44 unitary spin-down |0> and/or|1> qubit operators, suggesting 9840 two-level spin-down qubit operatorsto lay out 820 (CNOT) QCAs and 237 one-level spin-down qubit operatorsto lay out 79 CNOT QCAs in frequency domains. u, -related amplitude andangular momentum of quantum wave of FIG. 6 m in time domains, whereinthe RT50T tuned amplitude of polaritons is around 2.0E-7 within0s-1.6E-7s. v, RTD50T tuned polaritons-driven symmetry 615 two-level and237 one-level spin-up qubit operator networks with 44 unitary spin—|0>and/or |1> qubit operators, suggesting 9840 two-level spin-up qubitoperators to lay out 820 (CNOT) QCAs and 237 one-level spin-up qubitoperators to lay out 79 CNOT QCAs in time domains. w, The average lasermicro-PL spectrum of 3 measurements with s.d. for the FIG. 6 a afteradding an external spinning magnetic field of RTD110T, wherein the PLpeak is visible around 500 nm wavelength with fluorescence intensityfrom about 600 a.u. through smooth processing. x, -related amplitudeand angular momentum of quantum wave of FIG. 6 w in frequency domains,wherein the RTD110T tuned amplitude of polaritons is around 2.75E-8within 0 Hz-2.0E-7 Hz. y, Polaritons-driven 2 one-level non-symmetryspin-up qubit operator networks with double spin echo and unitary qubitoperator |0>, suggesting 8 spin-up qubit operators to form 1 QCA with 3carries for permutations of |0> and/or |1>. z, -related amplitude andangular momentum of quantum wave of FIG. 6 w in time domains, whereinthe RTD110T tuned amplitude of polaritons is around 1.375E-8 within0s-2.0E-7s. I, Polaritons-driven 2 one-level non-symmetry spin-downqubit operator networks with double spin echo and unitary qubit operator|1>, suggesting 8 spin-up qubit operators to form 1 QCA with 3 carriesfor permutations of |0> and/or |1>. 120 unitary |0> and/or |1> qubitoperators in time domains. II, The average laser micro-PL spectrum of 14measurements with s.d. for the FIG. 6 a after adding an externalspinning magnetic field of 70D, wherein the double-peaked PL spectrum isvisible around 250 nm, 1250 nm and 1750 nm wavelengths with fluorescenceintensity from about 1400 a.u., 3000 a.u. and 1000 a.u. through smoothprocessing. III, -related amplitude and angular momentum of quantumwave of FIG. 6II in frequency domains, wherein the 70D tuned amplitudeof polaritons is around 1.5E-7 within 0 Hz-1.5E-7 Hz. IV,Polaritons-driven 413 two-level spin-down qubit operator networks and106 one-level qubit operator networks with 183 unitary spin-down |0>and/or |1> qubit operators, suggesting 6608 two-level spin-down qubitoperators to form 1521 majority QCAs with 3 carries for permutations,and 424 one-level spin-down qubit operators to form 84 majority QCAswith 4 carries for permutations, and as well as double spin echo fornon-symmetry one-level and two-level spin-down qubit operator networks.V, -related amplitude and angular momentum of quantum wave of FIG. 6IIin time domains, wherein the 70D tuned amplitude of polaritons is around7.5E-8 within 0 Hz-1.5E-7 Hz. VI, Polaritons-driven 387 two-levelspin-up qubit operator networks and 125 one-level qubit operatornetworks with 163 unitary spin-up |0> and/or |1> qubit operators,suggesting 7392 two-level spin-up qubit operators to form 1478 majorityQCAs with 2 carries for permutations, and 500 one-level spin-up qubitoperators to form 100 majority QCAs, and as well as double spin echo fornon-symmetry one-level and two-level spin-down qubit operator networks.VII, The average laser micro-PL spectrum of 6 measurements with s.d. forthe FIG. 6 a after adding an external spinning magnetic field of 104D,wherein the double-peaked PL spectrum is visible around 475 nm, 550 nmand 575 nm wavelengths with fluorescence intensity from about 2750 a.u.,3000 a.u. and 1250 a.u. through smooth processing. VIII, -relatedamplitude and angular momentum of quantum wave of FIG. 6VII in frequencydomains, wherein the 104D tuned amplitude of polaritons is around1.25E-7 within 0 Hz-1.65E-7 Hz. IX, Polaritons-driven 151 two-levelspin-down qubit operator networks and 74 one-level spin-down qubitoperator networks with 98 unitary spin-down |0> and/or |1> qubitoperators, suggesting 2416 two-level spin-down qubit operators to form485 majority QCAs with 1 carry for operator permutation, and 296one-level spin-down qubit operators to form 58 majority QCAs with 6carries for operator permutations, and as well as double spin echo fornon-symmetry one-level and two-level spin-down qubit operator networks.X, -related amplitude and angular momentum of quantum wave of FIG. 6VIIin time domains, wherein the 104D tuned amplitude of polaritons isaround 6.0E-8 within 0s-1.65E-7s. XI, Polaritons-driven 635 two-levelspin-up qubit operator networks and 78 one-level spin-up qubit operatornetworks with 81 unitary spin-up |0> and/or |1> qubit operators,suggesting 10160 two-level spin-up qubit operators to form 2032 majorityQCAs, and 312 one-level spin-up qubit operators to form 62 majority QCAswith 2 carries for operator permutations, and as well as double spinecho for non-symmetry one-level and two-level spin-up qubit operatornetworks and permutations. The spin-down and spin-up qubit operatornetworks in FIGS. 6 k, 6 l, 6 o, 6 q, 6 t, 6 v, 6 y, 6I, 6IV, 6VI, 6IXand 6XI satisfy the Σ(2^(n)) binary code matrix.

DETAILED DESCRIPTION

Turning self-assembled pharmaceuticals and a bio-redox single electronsystem into redox nanomedicine quantum dot room temperaturesuperconductor qubit networks onto graphite and silicon substrates undera 10 class clean environment and a spatial distance constraint of 0.1Å-200 Å including unitary, binary, ternary, quaternary quinary andhexahedral complexes described herein demonstrate electrostatic stackedcoordinate of an antioxidase antioxidant, agonists of β-adrenergic andP₂ purinergic receptors, a phenylalkylamine (benzalkonium) calciumchannel blocker and/or a bio-redox single electron system of either XO:X or X from a liquid phase state to a co-crystallized soft condensatestate.

Advantageous compositions of turning self-assembled pharmaceuticals anda bio-redox single electron system into molecular scalesize-controllable redox nanomedicine quantum dot room temperaturesuperconductor qubit networks with cross-bar, hexahedral stacked,electrostatic hybrid geometrical nanometer architectures includeisoprenaline molecular numbers in a range of about single molecule toabout 10¹⁵, adenosine triphosphate in a range of about single moleculeto about 10¹⁹, verapamil in a range of about single molecule to about10¹⁴, and/or superoxide dismutase in a range of about single molecule toabout 10¹³, each pharmaceutical ingredient and its binary, ternaryand/or quaternary complexes is combined with either bio-redox singleelectron system of XO:X in a molecular mixture ratio of 1:20, whereinthe molecular number of X may be in a range of about 1-20 singlemolecules to about 3×10¹⁶-3×10¹⁹ in a liquid phase. This liquidpharmaceutical composition targets hypoxia-mediated key loops incardiopulmonary and cerebral functional disorders and/or carcinomametastasis, including the decline in β-adrenergic and P₂-purinergicreceptor signal transduction, superoxide anion induced endothelialinjuries, and an elevated intracellular calcium influx.

This preparation process employs molecular scale coordinates toself-assemble unitary, binary, ternary, quaternary, quinary and/orhexahedral redox nanomedicine quantum dot room temperaturesuperconductor qubit networks in the cross-bar electrostatic andhexahedral-stacked quantum and/or magnetic tunnel junctions (QTJs and/orMTJs) patterns through either droplets onto the substrates or immersingsubstrates in the unitary, binary, ternary, and/or quaternarypharmaceutical standard solutions of isoprenaline, verapamil, superoxidedismutase, and/or adenosine triphosphate in combination with a bio-redoxsingle electron system of XO:X or X alone according to the L₁₆(2)¹⁵ andthe L₉(3)⁴ orthogonal design protocols. The electrostatic cross-barstacked and hexahedral 3D geometrical architectures and theirpreparation process are advantageous for nano-drug discovery and highdensity and high performance quantum bit informatics devices as well asphotoelectron sensing materials.

The molecular scale electrostatic stacked quantum and/or magnetic tunneljunction (QTJ and/or MTJ) and (QCA) property of the redox nano-medicinequantum dot room temperature superconductor qubit networks is presentedby the bio-redox single electron spin-up and spin-down tunnelingtransports resulting from tunneling of electron spin-up into the upperlayer electrostatic stacked quantum dots and tunneling of electronspin-down into the lower layer electrostatic stacked quantum dots statein I-V curves, their first derivatives, laser micro-PL spectra, theirFFTs and their first derivatives of relative phases and FFTs infrequency and time domains that are -related QCVs, including angularmomentum of single electron spins, amplitude of quantum waves, phasetransition dynamics of qubit operator networks within a range of aboutnHz to about pico-seconds with about sub-10⁻¹⁹ eV energy fluctuations. .

The feature of the redox nano-medicine quantum dot room temperaturesuperconductor qubit networks is identified by -related ±½πN symmetryor non-symmetry spin-down and spin-up phase transition degrees thatsatisfy ±½πN Hadamard and/or Pauli Z-gated qubit operator networks andtwo-level symmetry spin-down and spin-up XOR-gated qubit operatornetworks with carries, spin echo and unitary qubit operators. Allsymmetry or non-symmetry spin-down and spin-up phase transition degreessatisfy -related binary code matrix of Hamiltonians in a superconductorqubit operator network manner of either Σ2^(n), Σ2²·2^(n), Σ2^(n+1),Σ2^(2n)·2^(2n), Σ2^(2n+)·2^(2n+1) or Σ2^(2n+1).

The -related qubit metrology in the invention is a measurement methodstandard of C-AFM and laser micro-PL spectrum in combination with theL₁₆(2)¹⁵ and L₉(3)⁴ orthogonal optimization methods, and ORIGINmathematical analyses (available from OriginLab Co., Northampton,Mass.), comprising calibration of C-AFM tip and laser micro-PL spectrumsystem as well as standard samples under clean and dry environments, novibrations and no noise interference, as well as non-contact tip modesto secure reproducible and traceable as well as convincible with errbars and statistical significance P value tests.

A key composition of this invention is the optimum self-assembly ofuni-, bi-, tri-, tetra-, quin- and/or hexa-elements of isoprenaline (aβ-adrenergic receptor agonist), adenosine triphosphate (a P₂-purinergicreceptor agonist), verapamil (a phenylalkylamine calcium channelblocker), superoxide dismutase (an antioxidase antioxidant) and/or abio-redox single electron system of XO and X respectively at a desiremolecular mixture ratio through controlling the spatial distanceconstraint of 0.1 Å-200 Å in the liquid phase for a desired period undera 10 class clean environment to secure single molecular scaleelectrostatic stacked 3D nanometer co-crystallized quantum dot roomtemperature superconductor qubit network architectures onto thesubstrates in the L₁₆(2)¹⁵ and L₉(3)⁴ orthogonal design protocols.

Unitary redox nanomedicine quantum dot room temperature superconductorqubit networks are respectively self-assembled onto substrates of eitherthe 8-12 Ω·cm p-doped silicon surface with hydrogen bonds, the 0.01-0.05Ω·cm n-doped silicon surface with the hydrogen bonds or the cleangraphite surface, under a 10 class clean environment for a desired timeperiod of either about 30-60 minutes onto the graphite substrate at roomtemperature or about 8-12 hours onto the silicon substrates at from −4°C. to −20° C., according to (i) 1:0:0:0; (ii) 0:1:0:0; (iii) 0:0:1:0;and/or (iv) 0:0:0:1 complex molecular mixture preparation processes of abio-redox single electron-pharmaceutical hybrid system, wherein redoxpharmaceutical ingredients comprise verapamil, isoproterenol, superoxidedismutase, adenosine triphosphate in combination with either XO:X in a1:20 molecular mixture ratio or X through 0.1 Å-200 Å spatial distanceconstraint in the liquid phase for 3D stacked molecular architectures.

Binary redox nanomedicine quantum dot room temperature superconductorqubit networks are respectively fabricated onto the p-doped (8-12 Ω·cm)or the n-doped (0.01-0.05 Ω·cm) silicon substrate are respectivelyfabricated onto substrates of either the 8-12 Ω·cm p-doped siliconsurface with hydrogen bonds, the 0.01-0.05 Ω·cm n-doped silicon surfacewith the hydrogen bonds or the clean graphite surface, under a 10 classclean environment for a desired time period of either about 30-60minutes onto the graphite substrate at room temperature or about 8-12hours onto the silicon substrates at from −4° C. to −20° C., accordingto (i) 1:1:0:0; (ii) 1:0:1:0; (iii) 1:0:0:1; (iv) 0:1:1:0; (v) 0:1:0:1and/or (vi) 0:0:1:1 complex molecular mixture preparation processes of abio-redox single electron-pharmaceutical hybrid system, wherein redoxpharmaceutical ingredients comprise verapamil, isoproterenol, superoxidedismutase, adenosine triphosphate in combination with either XO:X in a1:20 molecular mixture ratio or X through 0.1 Å-200 Å spatial distanceconstraint in the liquid phase for 3D stacked molecular architectures.

Ternary redox nanomedicine quantum dot room temperature superconductorqubit networks are respectively manufactured onto the p-doped (8-12Ω·cm) or the n-doped (0.01-0.05 Ω·cm) silicon substrate are respectivelyfabricated onto substrates of either the 8-12 Ω·cm p-doped siliconsurface with hydrogen bonds, the 0.01-0.05 Ω·cm n-doped silicon surfacewith the hydrogen bonds or the clean graphite surface, under a 10 classclean environment for a desired time period of either about 30-60minutes onto the graphite substrate at room temperature or about 8-12hours onto the silicon substrates at −4° C.-−20° C., according to (i)1:1:1:0; (ii) 1:0:1:1; (iii) 1:1:0:1; and/or (iv) 0:1:1:1 complexmolecular mixture preparation processes of a bio-redox singleelectron-pharmaceutical hybrid system, wherein redox pharmaceuticalingredients comprise verapamil, isoproterenol, superoxide dismutase,adenosine triphosphate in combination with either XO:X in a 1:20molecular mixture ratio or X through 0.1 Å-200 Å spatial distanceconstraint in the liquid phase for 3D stacked molecular architectures.

Quaternary redox nanomedicine quantum dot room temperaturesuperconductor qubit networks are respectively synthesized ontosubstrates of either the 8-12 Ω·cm p-doped silicon surface with hydrogenbonds, the 0.01-0.05 Ω·cm n-doped silicon surface with the hydrogenbonds or the clean graphite surface, under a 10 class clean environmentfor a desired time period of either about 30-60 minutes onto thegraphite substrate at room temperature or about 8-12 hours onto thesilicon substrates at −4° C.-−20° C., according to (i) 1:1:1:1; (ii)1:2:2:2; (iii) 1:3:3:3; (iv) 2:1:2:3; (v) 2:2:3:1; (vi) 2:3:1:2; (vii)3:1:3:2; (viii) 3:2:1:3; and/or (ix) 3:3:2:1 complex molecular mixturepreparation processes of a bio-redox single electron-pharmaceuticalhybrid system, wherein redox pharmaceutical ingredients compriseverapamil, isoproterenol, superoxide dismutase, adenosine triphosphatein combination with either XO:X in a 1:20 molecular mixture ratio or Xthrough 0.1 Å-200 Å spatial distance constraint in the liquid phase for3D stacked molecular architectures.

The I-V curves, the laser micro-PL spectra, their FFTs, their firstderivatives of relative phases in frequency and time domains (dr/df=ΔE/and dr/dt=ΔE/ for -related QCVs) and their FFTs of self-assembledunitary, binary, ternary, quaternary, quinary and hexahedral complexesof this invention can generate 24 arrays of composition data and 24size-controlled molecular scale stacked patterns at a nanometer and/oran atomic level. The 3D topographic structures of redox nanomedicinequantum dot room temperature superconductor qubit networks may beidentified by C-AFM images, as shown in FIGS. 1-5. The spatial stackedsizes of redox nanomedicine quantum dot room temperature superconductorqubit networks may be in a range of about one angstrom to about a fewhundred angstroms. The finest redox nanomedicine quantum dot roomtemperature superconductor qubit networks may be about 26 angstroms. Thesmallest spatial size of a size-controlled molecular scale stacked redoxnanomedicine quantum dot room temperature superconductor qubit networktopographic structure may be sub-angstroms about 0.8 Å.

The self-assembled redox nanomedicine quantum dot room temperature qubitnetworks possess hexahedral stacked molecular networks and 3D cross-barshape, as well as controllable ultra-fine QTJs and/or MTJs with-related single electron spin tunneling and/or photon-electroncoupling/co-tunneling into the 3D electro-statically coupled quantum dotnetworks, as shown by their topographic structure images, currentspectra, I-V curves and double-peaked PL spectra as well as their QCVsin FIG. 1 a-d, FIG. 2 a-d, FIG. 3 a-d, FIG. 4 a-f and FIG. 5 a-i. Thisinvention is advantageous in molecular scale electronics and quantum bitmemory devices as well as new nanometer scale bio-photoelectron sensors.

The preparation process is to lay out redox nanomedicine quantum dotmatrix of single molecular scale π-π stackedenzyme-pharmaceutical-nuclear acid hybrid mono-layer networks onto asubstrate through a spatial distance constraint, bonding andanti-bonding states, πorbits of CH₂═CH—CH═CH₂ and −N═N—, and non-bondingn orbits of —OH, —NH₂ and/or −Cl, as well as single photondonors-receptors of N- and NH₂-contained aromatic structures withinredox nanomedicine molecules in a clean environment. Droplets ofPharmaceuticals are prepared according to pharmaceutical standardsissued by the Ministry of Health in China. Droplets of nanomedicine aremade by the uni-, bi-, tri-, tetra-, quin- and/or hexa-hybrid ofverapamil hydrochloride, isoprenaline hydrochloride, superoxidedismutase, and adenosine triphosphate in combination with a bio-redoxsingle electron system of either XO: X or X at a desire molecularmixture ratio. Lay-outs of redox nanomedicine quantum dot roomtemperature superconductor qubit networks onto substrates are accordingto L₁₆(2)¹⁵ and L₉(3)⁴ orthogonal design protocols in a liquid phase fora desired period by modulating spatial distance constraints in a rangeof about 0.1 Å to about 200 Å under a clean environment about 10 class,wherein the uni-, bi-, tri-, tetra-, quin- and/or hexa-hybrid ofverapamil hydrochloride, isoprenaline hydrochloride, superoxidedismutase, and adenosine triphosphate in combination with a bio-redoxsingle electron system of either XO: X or X are secured to be stacked inan electrostatic contact manner. A unitary, binary, ternary, quaternary,quinary and/or hexahedral redox nanomedicine quantum dot roomtemperature superconductor qubit network may be formed onto a substrateof either a graphite, a 8-12 Ω·cm p-doped silicon chip with H-bonds or a0.01-0.05 Ω·cm n-doped silicon chip with H-bonds for either 30-60minutes at room temperature, 8-12 hours or 96 hours around −4° C.-−20°C. by a droplet hetero-molecular core-shell quantum dot lattice epitaxyin a desired molecular scale mixture ratio under a 10-class cleanenvironment.

A unitary, binary, ternary, quaternary, quinary and/or hexahedraldroplet hetero-molecular core-shell quantum dot lattice epitaxy maycomprise verapamil hydrochloride, isoprenaline hydrochloride, superoxidedismutase, and adenosine triphosphate in combination with a bio-redoxsingle electron system of either XO: X or X in a desired molecularmixture ratio according to L₁₆(2)¹⁵ and L₉(3)⁴ orthogonal designprotocols through hetero-molecular-crystal lattice epitaxy spatialdistance constraints in a range of about 0.1 Å to about 200 Å.

A unitary desired molecular number of a hybrid redox nanomedicinedroplets for hetero-molecular core-shell quantum dot lattice epitaxy maybe according to (i) 1:0:0:0; (ii) 0:1:0:0; (iii) 0:0:1:0; (iv) 0:0:0:1;and combinations thereof, in an L₁₆(2)¹⁵ orthogonal design protocol,wherein verapamil hydrochloride droplet may be in a range of aboutsingle molecules to about 10¹⁴; a unitary desired molecular number of aisoprenaline hydrochloride droplet may be in a range of about singlemolecules to about 10¹⁵; a unitary desired molecular number of asuperoxide dismutase buffer droplet may be in a range of about singlemolecules to about 10¹³; a unitary desired molecular number of anadenosine triphosphate buffer droplet may be in a range of about singlemolecules to about 10¹⁹; a desired molecular number of XO:X may be 1:20;and a desired molecular number of X may be in a range of about 1-20single molecules to about 10¹⁶-3×10¹⁹.

A binary desired molecular number of a hybrid redox nanomedicinedroplets for hetero-molecular core-shell quantum dot lattice epitaxy maybe according to (i) 1:1:0:0; (ii) 1:0:1:0; (iii) 1:0:0:1; (iv) 0:1:0:0;(v) 0:1:0:1; (vi) 0:0:1:1, and combinations thereof, in an L₁₆(2)¹⁵orthogonal design protocol to mix a verapamil hydrochloride droplet in amolecular number about single molecules to about 10¹⁴, an isoprenalinehydrochloride droplet in a molecular number about single molecules toabout 10¹⁵, a superoxide dismutase buffer droplet in a molecular numberabout single molecules to about 10¹³, an adenosine triphosphate bufferdroplet in a molecular number about single molecules to about 10¹⁹ pluseither 1:20 XO:X or X in a molecular number about 1-20 single moleculesto about 3×10¹⁶-3×10¹⁹.

A ternary desired molecular number of a hybrid redox nanomedicinedroplets for hetero-molecular core-shell quantum dot lattice epitaxy maybe according to (i) 1:1:1:0; (ii) 1:0:1:1; (iii) 1:1:0:1; and/or (iv)0:1:1:1 and combinations thereof, in an L₁₆(2)¹⁵ orthogonal designprotocol to mix a verapamil hydrochloride droplet in a molecular numberabout single molecules to about 10¹⁴, an isoprenaline hydrochloridedroplet in a molecular number about single molecules to about 10¹⁵, asuperoxide dismutase buffer droplet in a molecular number about singlemolecules to about 10¹³, an adenosine triphosphate buffer droplet in amolecular number about single molecules to about 10¹⁹ plus either 1:20XO:X or X in a molecular number about 1-20 single molecules to about3×10¹⁶-3×10¹⁹.

A quaternary desired molecular number of a hybrid redox nanomedicinedroplets for hetero-molecular core-shell quantum dot lattice epitaxy maybe according to (i) 1:1:1:1; (ii) 1:2:2:2; (iii) 1:3:3:3; (iv) 2:1:2:3;(v) 2:2:3:1; (vi) 2:3:1:2; (vii) 3:1:3:2; (viii) 3:2:1:3; and/or (ix)3:3:2:1 and combinations thereof, in an L₉(3)⁴ orthogonal designprotocol to mix a verapamil hydrochloride droplet in a molecular numberabout single molecules to about 10¹⁴, an isoprenaline hydrochloridedroplet in a molecular number about single molecules to about 10¹⁵, asuperoxide dismutase buffer droplet in a molecular number about singlemolecules to about 10¹³, an adenosine triphosphate buffer droplet in amolecular number about single molecules to about 10¹⁹ plus either 1:20XO:X or X in a molecular number about 1-20 single molecules to about3×10¹⁶-3×10¹⁹.

In the L₁₆(2)¹⁵ orthogonal design protocol, there are 4 differentunitary hybrid redox nanomedicine hetero-molecular core-shell quantumdot lattice epitaxy droplets, 6 different binary hybrid redoxnanomedicine hetero-molecular core-shell quantum dot lattice epitaxydroplets, 4 different ternary hybrid redox nanomedicine hetero-molecularcore-shell quantum dot lattice epitaxy droplets, 1 quaternary hybridredox nanomedicine hetero-molecular core-shell quantum dot latticeepitaxy droplets, and a blank control group. In the L₉(3)⁴ orthogonaldesign protocol, there are 9 different quaternary hybrid redoxnanomedicine hetero-molecular core-shell quantum dot lattice epitaxydroplets at three molecular mixture ratios. Hybrid redox nanomedicinehetero-molecular core-shell quantum dot lattice epitaxy droplets are theunitary, binary, ternary and quaternary nanomedicine in combination with1:20 XO:X or X.

The uni-, bi-, tri-, tetra-, quin- and/or hexa-hybrid redox nanomedicinehetero-molecular quantum dot lattice epitaxy droplets may assembly asredox nanomedicine quantum dot room temperature superconductor qubitnetworks, wherein a redox nanomedicine hetero-molecular core-shellquantum dot lattice, a three-quantum particle transistor and a qubitcentral processor unit may be included.

Example 1

Pharmaceutical liquids are prepared according to the pharmaceuticalstandards issued by the Ministry of Health in China. FIG. 1 a-d isdrawings of a C-AFM current spectrum, a I-V curve, a dI-dV conductancespectrum, and an average laser micro-PL spectra as well as -relatedpower-frequency-phase and power-time-phase spectra derived from the1^(st) derivatives of relative phase FFTs obtained from the 0:1:0:0product of Example 1 according to the L₁₆(2)¹⁵ orthogonal designprotocol under a 10 class clean environment.

-   -   i. An isoprenaline hydrochloride pharmaceutical liquid is        prepared at a concentration of 2 mg/100 mL according to a SFDA        standard.    -   ii. An isoprenaline hydrochloride pharmaceutical droplet may        comprise the molecular number of about 10¹⁴ isoprenaline        hydrochloride molecules to about 10¹⁵ isoprenaline hydrochloride        molecules.    -   iii. A bio-redox single electron system is made in physiological        buffer solution of xanthine oxidase (XO) and xanthine (X)        according to a 1:20 molecular mixture ratio, and the desired        molecular xanthine number may be in a range of about 3×10¹⁶ X        molecules to about 3×10¹⁹ X molecules.    -   iv. A droplet of XO-X-isoproterenol hydrochloride hybrid is        prepared onto a 0.01-0.05 Ω·cm n-doped silicon substrate surface        according to a desired molecular mixture ratio of 0:1:0:0 in the        L₁₆(2)¹⁵ by controlling the spatial distance of 0.1 Å-200 Å at        −20° C. for 8-12 hours, up to forming to a redox nano-drug        quantum dot network lattice through a droplet crystal lattice        hetero-epitaxy bottom-up self-assembly approach.    -   v. At a room temperature and in air, C-AFM is used for imaging        the topographic structure and current spectrum of a        self-assembled redox nano-drug quantum dot network lattice,        probing its I-V curve and the 1^(st) derivative of I-V curve        (dI/dV), as shown in FIG. 1 a-c.    -   vi. At a room temperature and in air, a laser micro-PL spectrum        system tool characterizes an average PL spectrum with standard        deviation (s.d.), and -related symmetry spin-down and spin-up        qubit network and its operator permutations in -related        power-frequency-phase and power-time-phase spectra, as indicated        in FIG. 1 d.

Example 2

Pharmaceutical liquids are prepared according to the pharmaceuticalstandards issued by the Ministry of Health in China. FIG. 2 a-d isdrawings of a C-AFM topographic structure image, average laser micro-PLspectra and -related symmetry and/or non-symmetry spin-down and spin-upqubit network features obtained from the 1:1:1:1 product of Example 2according to the L₁₆(²)¹⁵ orthogonal design protocol under a 10 classclean environment.

-   -   i. A verapamil hydrochloride pharmaceutical liquid is prepared        at a concentration of 2.5 mg/5 mL.    -   ii. An isoprenaline hydrochloride pharmaceutical liquid is        prepared at a concentration of 2 mg/100 mL.    -   iii. A physiological buffer solution of superoxide dismutase is        prepared at a concentration of 1 mg/2 mL.    -   iv. A physiological buffer solution of adenosine triphosphate is        prepared at a concentration of 20 mg/3.3 mL.    -   v. A verapamil hydrochloride pharmaceutical droplet may comprise        the molecular number of about 10¹² verapamil hydrochloride        molecules to about 10¹⁴ verapamil hydrochloride molecules.    -   vi. An isoprenaline hydrochloride pharmaceutical droplet may        comprise the molecular number of about 10¹⁴ isoprenaline        hydrochloride molecules to about 10¹⁵ isoprenaline hydrochloride        molecules.    -   vii. A superoxide dismutase buffer droplet may consist of about        10¹¹ superoxide dismutase molecules to about 10¹³ superoxide        dismutase molecules.    -   viii. An adenosine triphosphate buffer droplet may be made up of        about 10¹¹ adenosine triphosphate molecules to about 10¹⁹        adenosine triphosphate molecules.    -   ix. A bio-redox single electron system is made in physiological        buffer solution of xanthine oxidase (XO) and xanthine (X)        according to a 1:20 molecular mixture ratio, and the desired        molecular xanthine number may be in a range of about 3×10¹⁶ X        molecules to about 3×10¹⁹ X molecules.    -   x. A hexa-redox-pharmaceutical droplet hybrid is made by mixing        v, vi, vii, viii and ix according to a desired molecular mixture        ratio of 1:1:1:1 in the L₁₆(2)¹⁵ orthogonal design protocol.    -   vii. A hybrid droplet of x is prepared onto a 0.01-0.05 Ω·cm        n-doped silicon substrate surface by controlling the spatial        distance of 0.1 Å-200 Å at −20° C. for 8-12 hours, up to forming        to a redox nano-drug quantum dot network lattice through a        droplet crystal lattice hetero-epitaxy bottom-up self-assembly        approach.    -   xi. At a room temperature and in air, C-AFM is used for imaging        the topographic structure of a self-assembled redox nano-drug        quantum dot network lattice, as shown in FIG. 2 a.    -   viii. At a room temperature and in air, laser micro-PL spectrum        tool is used for characterizing 70D-, 70D150t-, 98D-, 101D-,        104D-, 109D-, 113D-, 117D-, RTD10t-, RTD50t-, RTD110t-tuned an        average laser micro-PL spectrum plus s.d., which is obtained        from 99 measurements to acquire -related symmetry and        non-symmetry spin-down and spin-up qubit network and its        operator permutations in -related power-frequency-phase and        power-time-phase spectra, as revealed in FIG. 2 b-d.

Example 3

Pharmaceutical liquids are prepared according to the pharmaceuticalstandards issued by the Ministry of Health in China. FIG. 3 a-d isdrawings of a C-AFM image, an average laser micro-PL spectra of 99measurements, and -related non-symmetry spin-down and spin-up qubitnetwork features obtained from the 1:1:1:1 product of Example 3according to the L₉(3)⁴ orthogonal design protocol under a 10 classclean environment.

-   -   i. A verapamil hydrochloride pharmaceutical liquid is prepared        at a concentration of 2.5 mg/5 mL.    -   ii. An isoprenaline hydrochloride pharmaceutical liquid is        prepared at a concentration of 2 mg/100 mL.    -   iii. A physiological buffer solution of superoxide dismutase is        prepared at a concentration of 1 mg/2 mL.    -   iv. A physiological buffer solution of adenosine triphosphate is        prepared at a concentration of 20 mg/3.3 mL.    -   v. A verapamil hydrochloride pharmaceutical droplet may comprise        the molecular number of about 10¹² verapamil hydrochloride        molecules to about 10¹⁴ verapamil hydrochloride molecules.    -   vi. An isoprenaline hydrochloride pharmaceutical droplet may        comprise the molecular number of about 10¹⁴ isoprenaline        hydrochloride molecules to about 10¹⁵ isoprenaline hydrochloride        molecules.    -   vii. A superoxide dismutase buffer droplet may consist of about        10¹¹ superoxide dismutase molecules to about 10¹³ superoxide        dismutase molecules.    -   viii. An adenosine triphosphate buffer droplet may be made up of        about 10¹¹ adenosine triphosphate molecules to about 10¹⁹        adenosine triphosphate molecules.    -   ix. A bio-redox single electron system is made in physiological        buffer solution of xanthine oxidase (XO) and xanthine (X)        according to a 1:20 molecular mixture ratio, and the desired        molecular xanthine number may be in a range of about 3×10¹⁶ X        molecules to about 3×10¹⁹ X molecules.    -   x. A hexa-redox-pharmaceutical droplet hybrid is made by mixing        v, vi, vii, viii and ix according to a desired molecular mixture        ratio of 1:1:1:1 in the L₉(3)⁴ orthogonal design protocol.    -   xi. A hybrid droplet of x is prepared onto a 0.01-0.05 Ω·cm        n-doped silicon substrate surface by controlling the spatial        distance of 0.1 Å-200 Å at −20° C. for 8-12 hours, up to forming        to a redox nano-drug quantum dot network lattice through a        droplet crystal lattice hetero-epitaxy bottom-up self-assembly        approach.    -   xii. At a room temperature and in air, C-AFM is used for imaging        the topographic structure of a self-assembled redox nano-drug        quantum dot network lattice, as shown in FIG. 3 a.    -   xiii. At a room temperature and in air, a laser micro-PL        spectrum system tool characterizes an average PL spectrum with        s.d., and -related non-symmetry spin-down and spin-up qubit        network and its operator permutations in -related        power-frequency-phase and power-time-phase spectra, as indicated        in FIG. 3 b-d.

Example 4

Pharmaceutical liquids are prepared according to the pharmaceuticalstandards issued by the Ministry of Health in China. FIG. 4 a-f depictsthree C-AFM images (a diameter 26 Å core-shell structure singlemolecular scale quantum dot; a spatial size 26 Å three-particletransistor with a source, a drain and a gate made by 3 spatial size 26 Åredox nanomedicine quantum dots in a triangle pattern; and a spatialsize 26 Å qubit CPU made by redox nanomedicine quantum dot networks), anaverage I-V curve with s.d., and -related electronic and qubit operatorprocessing features obtained from the 1:3:3:3 product of Example 4according to the L₉(3)⁴ orthogonal design protocol under a 10 classclean environment.

-   -   i. A verapamil hydrochloride pharmaceutical liquid is prepared        at a concentration of 2.5 mg/5 mL.    -   ii. An isoprenaline hydrochloride pharmaceutical liquid is        prepared at a concentration of 2 mg/100 mL.    -   iii. A physiological buffer solution of superoxide dismutase is        prepared at a concentration of 1 mg/2 mL.    -   iv. A physiological buffer solution of adenosine triphosphate is        prepared at a concentration of 20 mg/3.3 mL.    -   v. A verapamil hydrochloride pharmaceutical droplet may comprise        the molecular number of about 1 verapamil hydrochloride molecule        to about 9 verapamil hydrochloride molecules.    -   vi. An isoprenaline hydrochloride pharmaceutical droplet may        comprise the molecular number of about 1 isoprenaline        hydrochloride molecule to about 9 isoprenaline hydrochloride        molecules.    -   vii. A superoxide dismutase buffer droplet may consist of about        1 superoxide dismutase molecules to about 9 superoxide dismutase        molecules.    -   viii. An adenosine triphosphate buffer droplet may be made up of        about 1 adenosine triphosphate molecules to about 9 adenosine        triphosphate molecules.    -   ix. A bio-redox single electron system is made in physiological        buffer solution of xanthine (X) in a range of about 1 single X        molecule to about 9 single X molecules.    -   x. A hybrid droplet of v, vi, vii, viii and ix is prepared onto        a 8-12 Ω·cm p-doped silicon substrate surface by controlling the        spatial distance of 0.1 Å-200 Å at −4° C. for 96 hours, up to        forming to a redox nano-drug quantum dot network lattice through        a droplet crystal lattice hetero-epitaxy bottom-up self-assembly        approach.    -   xi. Washing the silicon substrate surface three times with clean        de-ionized water and keeping a dry surface for measurements.    -   xii. At a room temperature and in air, C-AFM is used for imaging        the topographic structure of a self-assembled redox nano-drug        quantum dot network lattice, as shown in FIG. 4 a-c, and probing        an average I-V curve obtained from 6 measurements with s.d., as        profiled in FIG. 4 d, as well as analyzing -related symmetry        spin-down and spin-up qubit network and its operator        permutations in -related power-frequency-phase and        power-time-phase spectra, as revealed in FIG. 4 e-f.

Example 5

Pharmaceutical liquids are prepared according to the pharmaceuticalstandards issued by the Ministry of Health in China. FIG. 5 a-i depictsa C-AFM image and an average I-V curve with s.d., a quantum Hall effect,-related quantum wave amplitudes and angular momentum dynamics infrequency and time domains and symmetry spin-down and spin-up roomtemperature superconductor qubit network features obtained from the1:1:1:1 of Example 5 according to the L₁₆(2)¹⁵ orthogonal designprotocol under a 10 class clean environment.

-   -   i. A verapamil hydrochloride pharmaceutical liquid is prepared        at a concentration of 2.5 mg/5 mL.    -   ii. An isoprenaline hydrochloride pharmaceutical liquid is        prepared at a concentration of 2 mg/100 mL.    -   iii. A physiological buffer solution of superoxide dismutase is        prepared at a concentration of 1 mg/2 mL.    -   iv. A physiological buffer solution of adenosine triphosphate is        prepared at a concentration of 20 mg/3.3 mL.    -   v. A verapamil hydrochloride pharmaceutical droplet may comprise        the molecular number of about 10¹² verapamil hydrochloride        molecules to about 10¹⁴ verapamil hydrochloride molecules.    -   vi. An isoprenaline hydrochloride pharmaceutical droplet may        comprise the molecular number of about 10¹⁴ isoprenaline        hydrochloride molecules to about 10¹⁵ isoprenaline hydrochloride        molecules.    -   vii. A superoxide dismutase buffer droplet may consist of about        10¹¹ superoxide dismutase molecules to about 10¹³ superoxide        dismutase molecules.    -   viii. An adenosine triphosphate buffer droplet may be made up of        about 10¹¹ adenosine triphosphate molecules to about 10¹⁹        adenosine triphosphate molecules.    -   ix. A bio-redox single electron system is made in physiological        buffer solution of xanthine oxidase (XO) and xanthine (X)        according to a 1:20 molecular mixture ratio, and the desired        molecular xanthine number may be in a range of about 3×10¹⁶ X        molecules to about 3×10¹⁹ X molecules.    -   x. A hexa-redox-pharmaceutical droplet hybrid is made by mixing        v, vi, vii, viii and ix according to a desired molecular mixture        ratio of 1:1:1:1 in the L₁₆(2)¹⁵ orthogonal design protocol.    -   xi. A hybrid droplet of x is prepared onto a clean graphite        substrate surface by controlling the spatial distance of 0 Å-200        Å at room temperature for 30-60 minutes, up to forming to a        redox nano-drug quantum dot network lattice through a droplet        crystal lattice hetero-epitaxy bottom-up self-assembly approach.    -   xii. At a room temperature and in air, C-AFM is used for imaging        the topographic structure of a self-assembled redox nano-drug        quantum dot network lattice, as shown in FIG. 5 a, probing an        average I-V curves of 5 measurements with s.d. in FIG. 5 b,        analyzing quantum resonance effect in dI-dV conductance spectrum        (FIG. 5 c), and -related quantum wave amplitudes and angular        momentum dynamics in frequency and time domains and symmetry        spin-down and spin-up room temperature superconductor qubit        network features, as revealed in FIG. 5 d-i.

Example 6

Pharmaceutical liquids are prepared according to the pharmaceuticalstandards issued by the Ministry of Health in China. FIG. 6 a-z and I-XIdepict a C-AFM image of self-assembled QCA arrays and itssingle-electron-driven and photoelectron co-tunneling-driven roomtemperature superconductor qubit operator network features as well asspinning magnetic field-tuned symmetry and non-symmetry CNOT andMajority QCA arrays in the room temperature superconductor qubitoperator networks obtained form the 2:3:1:2 product of Example 6.

-   -   i. A verapamil hydrochloride pharmaceutical liquid is prepared        at a concentration of 2.5 mg/5 mL.    -   ii. An isoprenaline hydrochloride pharmaceutical liquid is        prepared at a concentration of 2 mg/100 mL.    -   iii. A physiological buffer solution of superoxide dismutase is        prepared at a concentration of 1 mg/2 mL.    -   iv. A physiological buffer solution of adenosine triphosphate is        prepared at a concentration of 20 mg/3.3 mL.    -   v. A verapamil hydrochloride pharmaceutical droplet may comprise        the molecular number of about 10¹² verapamil hydrochloride        molecules to about 10¹⁴ verapamil hydrochloride molecules.    -   vi. An isoprenaline hydrochloride pharmaceutical droplet may        comprise the molecular number of about 10¹⁴ isoprenaline        hydrochloride molecules to about 10¹⁵ isoprenaline hydrochloride        molecules.    -   vii. A superoxide dismutase buffer droplet may consist of about        10¹¹ superoxide dismutase molecules to about 10¹³ superoxide        dismutase molecules.    -   viii. An adenosine triphosphate buffer droplet may be made up of        about 10¹¹ adenosine triphosphate molecules to about 10¹⁹        adenosine triphosphate molecules.    -   ix. A bio-redox single electron system is made in physiological        buffer solution of xanthine oxidase (XO) and xanthine (X)        according to a 1:20 molecular mixture ratio, and the desired        molecular xanthine number may be in a range of about 3×10¹⁶ X        molecules to about 3×10¹⁹ X molecules.    -   x. A hexa-redox-pharmaceutical droplet hybrid is made by mixing        v, vi, vii, viii and ix according to a desired molecular mixture        ratio of 2:3:1:2 in the L₉(3)⁴ orthogonal design protocol.    -   xi. A hybrid droplet of x is prepared onto a 0.01-0.05 Ω·cm        n-doped silicon substrate surface by controlling the spatial        distance of 0 Å-200 Å at −20° C. for 8-12 hours, up to forming        to a redox nano-drug quantum dot network lattice through a        droplet crystal lattice hetero-epitaxy bottom-up self-assembly        approach.    -   xii. At a room temperature and in air, C-AFM is used for imaging        the topographic structure of a self-assembled redox nano-drug        quantum dot room temperature superconductor QCA network lattice,        as shown in FIG. 6 a.    -   xiii. At a room temperature and in air, a laser micro-PL        spectrum system tool characterizes an average PL spectrum with        s.d., and polariton-driven room temperature superconductor        symmetry spin-down and spin-up qubit QCA networks and its        operator permutations in -related power-frequency-phase and        power-time-phase spectra, as well as external spinning magnetic        fields (RTD10t, RTD50t, RTD110t, 70D, 104D)—tuned symmetry to        non-symmetry QCA networks and operator permutations, as profiled        in FIG. 3 b-z and I-XI.

1. A process for constructing a redox nanomedicine quantum dot networkstructure operating -related room temperature qubit networks in aΣ(2^(n)) and/or a Σ(2^(n+1)) binary code matrix (a superconducting qubitand its networks) manner on a substrate surface at a temperature for aperiod, comprising: i) a step of preparing redox nanomedicine quantumdot network structure operating room temperature superconducting qubitnetworks by using a L₁₆(2)¹⁵ and a L₉(3)⁴ optimal protocols, wherein thei) step of preparing includes embodiments as follows: a) Respectivelyselecting 1:20 xanthine oxidease (XO):xanthine (X)-based redox buildingblocks of a uni-, a bi-, a tri and a tetra-hybrid of verapamilhydrochloride:isoproterenol hydrochloride:superoxide dismutase:adenosinetriphosphate containing t orbits of CH₂═CH—CH═CH₂ and —N═N—, n orbits of—OH, —NH₂ and —Cl, single bio-photon donors-receptors of N- and andNH₂-aromatic structures, a molecular hybrid ratio, and 10¹¹ to 10¹⁹molecules in a uni-, a bi-, a tri and a tetra-hybrid droplets, b)Choosing a single bio-electron system that includes 1:20 XO:X in adroplet, c) Respectively mixing (a) with (b) to form 1:20 XO:X-based auni-, a bi-, a tri- and a tetra-hybrid droplets of verapamilhydrochloride:isoproterenol hydrochloride:superoxide dismutase:adenosinetriphosphate, d) Respectively putting 1:20 XO:X-based a uni-, a bi-, atri- and a tetra-hybrid droplets of verapamilhydrochloride:isoproterenol hydrochloride:superoxide dismutase:adenosinetriphosphate on the substrate surface of either a 0.01 Ω·cm˜0.05 Ω·cmN-doped silicon chip with hydrogen bonding or a freshly isolatedgraphite surface, e) Respectively cooling 1:20 XO:X-based a uni-, a bi-,a tri- and a tetra-hybrid droplets of verapamilhydrochloride:isoproterenol hydrochloride:superoxide dismutase:adenosinetriphosphate on the substrate surface of the 0.01 Ω·cm˜0.05 Ω·cm N-dopedsilicon chip with hydrogen bonding at −4 ° C.˜−20° C. for 8˜12 hours, f)Respectively keeping 1:20 XO:X-based a uni-, a bi-, a tri- and atetra-hybrid droplets of verapamil hydrochloride:isoproterenolhydrochloride:superoxide dismutase:adenosine triphosphate on thesubstrate surface of the freshly isolated graphite surface at 4° C.˜18°C. for 30˜60 minutes, g) Making the redox nanomedicine quantum dotnetwork structure operating -related room temperature qubit networks ina 10 class ultra clean environment through a droplet bottom-upself-assembly approach, the step of (a) to (e), and an intermolecularspatial distance, and ii) A step of measuring electrical and opticalproperties of the redox nanomedicine quantum dot network structure tocharacterize superconducting qubit networks on the substrate of eitherthe 0.01 Ω·cm˜0.05 Ω·cm N-doped silicon chips with hydrogen bonding orthe graphite surface respectively by a C-AFM and a micro-PL spectrumtools at room temperature in air through using the L₁₆(2)¹⁵ and theL₉(3)⁴ optimal protocols, wherein the ii) step of measuring comprisesembodiments as follows: a) Imaging a topographic structure of the redoxnanomedicine quantum dot network on the substrate of either the 0.01Ω·cm˜0.05 Ω·cm N-doped silicon chip with hydrogen bonding or thegraphite surface by a C-AFM image, b) Measuring a current spectrum and aI-V curve of the redox nanomedicine quantum dot network on the substrateof either the 0.01 Ω·cm˜0.05 Ω·cm N-doped silicon chip with hydrogenbonding or the graphite surface by a C-AFM I-V curve measurement, c)Making a dI-dV conductance spectrum by the 1^(st) derivative of theC-AFM I-V curve to find a feature of superconductivity (a zero value ofthe dI-dV conductance spectrum at the zero bias potential in drawings of1 c and 5 c), d) Probing a micro-PL spectrum of the redox nanomedicinequantum dot network on the substrate of the 0.01 Ω·cm˜0.05 Ω·cm N-dopedsilicon chip with hydrogen bonding within ±5000 nm wavelengths by alaser micro-PL spectrum tool, e) Employing a toned spinning magneticfield of either 70D, 70D150T, 98D, 101D, 104D, 109D, 113D, 117D, RTD10T,RTD50T or RTD110T to measure a micro-PL spectrum of the redoxnanomedicine quantum dot network on the substrate of the 0.01 Ω·cm˜0.05Ω·cm N-doped silicon chip with hydrogen bonding within ±5000 nmwavelengths by a laser micro-PL spectrum tool, f) Analyzing an averageI-V curve, an average micro-PL spectrum, their 1^(st) derivatives of theaverage I-V curve and the average micro-PL spectrum and FFT in timedomains and frequency domains, and the -related power-frequency-phaseand power-time-phase spectra derived from the 1^(st) derivatives ofrelative phase and FFT in time domains and frequency domains (dr/dt ordr/df equals to ΔE/h) to acquire -related an bio-electron and/or abio-photon spin-up and spin-down state, a phase transition degree, aquantum continuous variation (QCV), a one-level and a two-level qubitoperator networking, permuting and processing, by the i) a) to g) stepof preparing to turn aromatic structures-, single bio-electrons-, singlebio-photons-based redox pharmaceuticals into a two dimensional (2D)molecular mono-layered redox nanomedicine quantum dot network structureand a three dimensional (3D) redox nanomedicine quantum dot networkstructure that operate -related room temperature superconducting qubitnetworks, of which their structures made in a liquid phase anddemonstrated by the ii) a) step of measuring, and their propertiesdemonstrated by the ii) b) to f) step of measuring includeembodiments, 1) wherein the structures operating -related roomtemperature superconducting qubit networks include co-crystallizedsemiconductor nano-particles (quantum dots), three-particle singleelectron transistors and qubit central processor units (QCPU), and the2D to 3D redox nanomedicine quantum dot network architectures, which aredemonstrated by the ii) a) step of measuring, i.e., by the C-AFM imagein working examples as follows: a) the 2D architecture of 5000 Å×5000 Åredox nanomedicine quantum dot network on the substrate of the 0.01Ω·cm˜0.05 Ω·cm N-doped silicon chip with hydrogen bonding is at roomtemperature in air demonstrated by the C-AFM image, b) the 3Darchitecture of a length 9000 Å a width 9000 Å and a height 85 Å redoxbio-molecular quantum dot network on the substrate of the 0.01 Ω·cm˜0.05Ω·cm N-doped silicon chip with hydrogen bonding is at room temperaturein air depicted by the C-AFM image, c) the 3D architecture of a length9500 Å, a width 9500 Å and a height 70 Å size-controlled redoxbio-molecular quantum dot network on the substrate of the 0.01 Ω·cm˜0.05Ω·cm N-doped silicon chip with hydrogen bonding is at room temperaturein air profiled by the C-AFM image, d) the 2D architecture ofsize-controllable core-shell quantum dot network at a diameter 2.6 nm,three-particle single bio-electron transistor (2.6 nm) and 2.6 nm redoxnanomedicine room temperature qubit central processor unit (CPU)self-assembled by redox biopharmaceutical molecules on the substrate of0.01 Ω·cm˜0.05 Ω·cm N-doped silicon chip with hydrogen bonding is atroom temperature in air revealed by the C-AFM image, e) the 3Darchitecture of 8000 Å×8000 Å×200 Å redox nanomedicine quantum dotnetwork on the graphite substrate surface is at room temperature in airrevealed by the C-AFM image; and 2) A -related photoelectrical featurepertaining to above redox nanomedicine quantum dot networks on thesubstrate of either 0.01 Ω·cm˜0.05 Ω·cm N-doped silicon chips withhydrogen bonding or graphite surfaces is at room temperature in airdemonstrated by the ii) b) to f) step of measuring in working examplesas follows: (1) The feature of h-related single bio-electrons- andsingle bio-photons-driven symmetry spin-up and spin-down qubit operatorprocessing up to phase transition degrees ±2364 pertaining to the 1) a)structure is respectively at room temperature in air demonstrated by theii) b) to f) step of measuring, of which, the ii) b) step of measuringshow (i) symmetry electron spin-up and spin-down current hysteresisloops including (a) ±0.05 pA within ±0.25 V bias potentials, (b) ±45 pAwithin ±6 V bias potentials, (c) ±0.65 pA within ±10 V bias voltages,and (ii) a 0.01 nA quantum resonance switching-on current and a −0.07 nAquantum resonance switching-off current; the ii) b) and f) step ofmeasuring demonstrates h-related symmetry spin-up and spin-down phasetransition degrees ±2364 by complex analyses of the average micro-PLspectrum, the 1^(st) derivative and FFT in time domains and frequencydomains, the 1^(st) derivative of relative phase and FFT in time domainsand frequency domains, (2) The feature of h-related singlebio-electron-driven symmetry electron spin-up and spin-down qubitoperator processing up to phase transition degrees ±34200 pertaining tothe 1) d) structure is at room temperature in air demonstrated by theii) b) and f) step of measuring, i.e., measurements and analyses of theaverage C-AFM I-V curve and FFT, the 1^(st) derivative of relative phaseand FFT in time domains and frequency domains, (3) the feature ofh-related ±½ at Pauli Z-, Hadamard- and XOR-gated one-level andtwo-level qubit operator networks pertaining to the 1) b) structure isrespectively at room temperature in air demonstrated by the ii) d) to f)step of measuring, i.e., serial analyses of both the C-AFM I-V curve andthe micro-PL spectrum, their 1^(st) derivatives and FFT in time domainand frequency domain, and their 1^(st) derivatives of relative phase andFFT in time domains and frequency domains, of which, spinning magneticfields of 70D, 70D150T, 98D, 101D, 104D, 109D, 113D, 117D, RTD10T,RTD50T and RTD110T, and electronic fields of ±10 V bias potentialsmodulate (i) h-related symmetry spin-up and spin-down phase transitiondegrees including (a) 0, ±2400, (b) 0, ±2440, (c) 0, ±16956, (d) 0,±32400, (e) 0, ±186400, (f) 0, ±202320; and (ii) h-related non-symmetryspin-up and spin-down phase transition degrees including (a) 180, 2254,−2250, (b) 180, 48787, 21798, 387173, 180, 180, −48427, −217620,−380813, 180, (c) 180, 2474, 180, 180, −247, 180, (d) 180, 102060, 180,180, −101700, 180, (e) 180, 192420, 180, 180, −192060, 180; within (ii),there is a spin echo (the phase transition degrees 180), and C-AFM I-Vcurves reveal non symmetry electron current hysteresis loops of 0.1pA˜10 pA spin-up currents and −0.05 pA˜−25 pA spin-down currents within±5 V˜±7.5 V, (4) the feature of h-related single bio-photoelectronco-tunneling-driven symmetry and non-symmetry spin-up and spin-downqubit operator processing pertaining to a 3D structure is at roomtemperature in air demonstrated by double peaked micro-PL spectra at 550nm and 575 nm wavelengths to show double peaks of (a) 250 a.u. and 1500a.u., (b) 4750 a.u. and 1750 a.u., (c) 3000 a.u. and 1750 a.u., (d) 4500a.u. and 1750 a.u. PL intensities, and (5) the feature of energy flipsof h-related single bio-photoelectron co-tunneling—driven one-level andtwo-level qubit operator networks pertaining to the 2D˜3D architecturesof redox nanomedicine quantum dot qubit networks is at room temperaturein air demonstrated in a range of about 5.4E-36 eV to about 631,00065eV, (6) the feature of quantum resonance tunneling peaks pertaining tothe 1) e) structure is at room temperature in air demonstrated by theii) c) step of measuring that show double quantum resonance tunnelingpeaks in a range of about 0.05 pA/V-0.2 pA/V within 0V-10V biaspotentials to about 0.45 pA-0.7 pA/V within ±10V bias potentials.
 2. Theprocess of claim 1, wherein the i) a) to g) preparing step includesembodiments as follows: i). in a 10 class clean environment, a liquidrequired for a redox nanomedicine quantum dot room operating temperaturesuperconducting qubit network is respectively prepared by using theL₁₆(²)¹⁵ and L₉(3)⁴ optimum protocols; ii). a 3-dimensional (3D)size-controlled redox nanomedicine quantum dot operating roomtemperature superconducting qubit network is respectively prepared byusing the L₁₆(2)¹⁵ and the L₉(3)⁴ optimum protocols in a liquid phase bya bottom-up self-assembly approach of controlling the intermolecularspatial distance from about 0.1 Å to about 200 Å; iii). droplets for arequired redox nanodrug quantum dot operating room temperaturesuperconducting qubit network are respectively put onto substratesurfaces (preferably selected from the group consisting of a freshlyseparated clean highly ordered graphite surface, a 0.01-0.05 Ω·cmn-doped silicon surface with hydrogen bonding) by using the L₁₆(2)¹⁵ andthe L₉(3)⁴ optimum protocols and national pharmaceutical manufacturestandards; or, a 0.01-0.05 Ω·cm n-doped silicon surface with hydrogenbonding or a 8-12 Ω·cm p-doped silicon surface with hydrogen bonding isrespectively immersed in the desired redox pharmaceutical hydrochlorideand physiological buffer solutions by using the L₁₆(2)¹⁵ and the L₉(3)⁴optimum protocols; iv). liquid redox pharmaceutical samples are kept atapproaching room temperature (4-18° C.) onto the graphite substrate for30-60 minutes, liquid redox pharmaceutical samples are coated onto thesilicon substrates at −4-−20° C. critical self-assembly temperature fora period of 8-12 or 96 hours, up to forming redox nanomedicine quantumdot networks with electron spins (qubits) in a Σ(2^(n)) and/or aΣ(2^(n+1)) binary code matrix (h-related superconducting qubits) manner;v). a droplet of hetero-molecular core-shell quantum dot is respectivelymade onto the substrate of either the 0.01-0.05 Ω·cm n-doped siliconsurface with hydrogen bonding or the graphite surface in the L₁₆(2)¹⁵and the L₉(3)⁴ optimum protocols by a hybrid redox nanomedicine dropletto form a hetero-molecular core-shell quantum dot, a three-quantum dottransistor, and a qubit central processor unit as well as the 2D˜3Dredox nanomedicine quantum dot network structure; vi) a hybrid redoxnanomedicine droplet is a 1:20 XO:X buffer solution-based uni-, bi-,tri-, and tetra-hybrid droplet of isoproterenol hydrochloride andadenosine triphosphate buffer solutions verapamil hydrochloride andsuperoxide dismutase buffer solutions to form the redox nanomedicinequantum dot operating room temperature qubit network, including theembodiment of a hetero-molecular core-shell quantum dot, a three-quantumdot transistor, and a qubit central processor unit as well as a 2D˜3Darchitecture of redox nanomedicine quantum dot network; vii). 24 groupsof molecular mixture ratios of verapamil hydrochloride: isoproterenolhydrochloride: superoxide dismutase buffer: adenosine triphosphatebuffer in combination with 1:20 xanthine oxidase (XO): xanthine (X) arethe 1:20 XO:X-based uni-, bi-, tri- and tetra-hybrids as follows: (i)1:0:0:0; (ii) 0:1:0:0; (iii) 0:0:1:0; (iv) 0:0:0:1; (v) 1:1:0:0; (vi)1:0:1:0; (vii) 1:0:0:1; (viii) 0:1:1:0; (ix) 0:1:0:1; (x) 0:0:1:1; (xi)1:1:1:0; (xii) 1:0:1:1; (xiii) 1:1:0:1; (xiv) 0:1:1:1; (xv) 1:1:1:1;(xvi) 1:2:2:2; (xvii) 1:3:3:3; (xviii) 2:1:2:3; (xix) 2:2:3:1; (xx)2:3:1:2; (xxi) 3:1:3:2; (xxii) 3:2:1:3; (xxiii) 3:3:2:1, andcombinations thereof, in the L₁₆(2)¹⁵ and the L₉(3)⁴ optimum protocols,wherein (xv) may be same a tetra-hybrid droplet in the L₁₆(2)¹⁵ and theL₉(3)⁴ optimum protocols, to form a redox nanomedicine quantum dotoperating room temperature qubit network, including a hetero-molecularcore-shell quantum dot lattice, a three-quantum dot transistor, a qubitcentral processor unit and 2D˜3D redox nanomedicine quantum dot networksmade by about trillion to about billion trillion molecules; and viii).washing the substrate surfaces of either 0.01-0.05 Ω·cm n-doped siliconchips with hydrogen bonding or the graphite (preferably at least 2times, optimal 2-4 times) with clean de-ionized water after 8-12 hoursare employed to secure a 2D molecular monolayer and a 3D architecture ofredox nanomedicine quantum dot network to be stacked onto the substratesof either 0.01˜0.05 Ω·cm n-doped silicon chips with hydrogen bonding orthe graphite surfaces, thereby forming 1:20 XO:X-based uni-, bi-, tri-,and tetra-embodiments of single molecular scale redox nanomedicinequantum dot operating room temperature superconducting qubit networks.3. The process of claim 1, wherein the i) a) to g) preparing stepincludes embodiments as follows: i) 24 hybrid systems of unitary,binary, ternary, quaternary redox nanomedicine ingredients (verapamilhydrochloride:isoprenaline hydrochloride:superoxide dismutase:adenosinetriphosphate) in combination with a bio-redox single bioelectronics(1:20 XO:X) to be the 1:20 XO:X-based uni-, bi-, tri- and tetra-hybridsystems are selectively synthesized by desired molecular mixture ratiosby using the L₁₆(2)¹⁵ and the L₉(3)⁴ design protocols; ii) Verapamilhydrochloride solutions are respectively prepared by molecular numbersin a range of about 10¹² to 10¹⁴; iii) Isoprenaline hydrochloridesolutions are respectively prepared by molecular numbers in a range ofabout 10¹⁴ to 10¹⁵; iv) Superoxide dismutase buffer solutions arerespectively prepared by molecular numbers in a range of about 10¹¹ to10¹³; v) Adenosine triphosphate physiological buffer solutions arerespectively prepared by molecular numbers in a range of about 10¹¹ to10¹⁹; vi) 1:20 XO:X buffer solutions of single electron system arerespectively prepared; and vii) 24 hybrid systems of unitary, binary,ternary, quaternary redox nanomedicine ingredients (verapamilhydrochloride:isoprenaline hydrochloride:superoxide dismutase:adenosinetriphosphate) in combination with a bio-redox single bioelectronicssystem (1:20 XO:X) are respectively prepared and mixed as of 1:20XO:X-based ii), iii), iv), and v), by using the L₁₆(2)¹⁵ and the L₉(3)⁴optimum protocols.
 4. The process of claim 1, wherein the 1) a) to g)preparing step of redox nanomedicine quantum dot operating roomtemperature superconducting qubit networks comprises the molecularhybrid ratio for preparing droplet hybrids, and the i) a) to g)preparing step includes embodiments as follows: i) Droplet hybrids ofunitary redox nanomedicine quantum dot operating room temperaturesuperconducting qubit network compositions are respectively prepared bya 1:20 XO:X-based unitary molecular mixture ratio of verapamilhydrochloride:isoprenaline hydrochloride:superoxide dismutase:adenosinetriphosphate in (i) 1:0:0:0; (ii) 0:1:0:0; (iii) 0:0:1:0; (iv) 0:0:0:1,and combinations thereof, by using the L₁₆(2)¹⁵ optimum protocol; ii)Droplet hybrids of binary redox nanomedicine quantum dot operating roomtemperature superconducting qubit network are respectively prepared by a1:20 XO:X-based binary molecular mixture ratio of verapamilhydrochloride:isoprenaline hydrochloride:superoxide dismutase:adenosinetriphosphate in (i) 1:1:0:0; (ii) 1:0:1:0; (iii) 1:0:0:1; (iv) 0:1:1:0;(v) 0:1:0:1; (vi) 0:0:1:1, and combinations thereof, by using theL₁₆(2)¹⁵ optimum protocol; iii) Droplet hybrids of ternary redoxnanomedicine quantum dot operating room temperature superconductingqubit network are respectively prepared by a 1:20 XO:X-based ternarymolecular mixture ratio of verapamil hydrochloride:isoprenalinehydrochloride:superoxide dismutase:adenosine triphosphate in (i)1:1:1:0; (ii) 1:0:1:1; (iii) 1:1:0:1; (iv) 0:1:1:1, and combinationsthereof, optimum L₁₆(2)¹⁵ orthogonal design protocol; iv) Droplethybrids of quaternary redox nanomedicine quantum dot operating roomtemperature superconducting qubit network are respectively prepared by a1:20 XO:X-based quaternary molecular mixture ratio of verapamilhydrochloride:isoprenaline hydrochloride:superoxide dismutase:adenosinetriphosphate in (i) 1:1:1:1; (ii) 1:2:2:2; (iii) 1:3:3:3; (iv) 2:1:2:3;(v) 2:2:3:1; (vi) 2:3:1:2; (vii) 3:1:3:2; (viii) 3:2:1:3; (ix) 3:3:2:1,and combinations thereof, by using the L₉(3)⁴ optimum protocol, wherein(i) may be overlapped in the L₁₆(2)¹⁵ optimum protocol; and v) 1:20 XO:Xis respectively mixed with i), ii), iii) and iv) to be 1:20 XO:X-baseduni-, bi-, tri- and tetra-hybrid droplets.
 5. The process of claim 1,wherein the ii) a) to f) measuring step further comprises characterizingthe redox nanomedicine quantum dot network with the followingparameters: C-AFM topographic structure images, I-V curve measurements,laser micro-PL spectra and both combinations, by using a hybrid ofphotons and single bio-electrons and an electron-photon coupling effectunder an external field of either a laser photon source, a gradientspinning magnetic field, and their combinations of which, smoothprocessing of parameters is employed.
 6. The process of claim 1, whereinthe ii) b) to f) measuring step pertaining to a -related redox singlebio-electron tunneling and single bio-photon tunneling-driven qubitprocessing under a gradient spin magnetic field-tuned -related quantumcontinuous variations (QCVs) may be at room temperature in air acquiredfrom faster Fourier transformation (FFT) of the average I-V curvesand/or the average PL spectra with s.d., their first derivatives ofrelative phases and FFT in frequency domains and time domains(dr/df=ΔE/ and dr/dt=ΔE/) for characterizing spin-down and spin-upqubit operator permutations, angular momentum of electron spins andphotoelectron co-tunneling, phase transition degrees, velocities andamplitudes of quantum waves in frequency domains and time domains. 7.The process of claim 1, wherein the ii) d) to f) measuring steppertaining to -related quantum optical property of a redox nanomedicinequantum dot operating room temperature superconducting qubit network isrespectively at room temperature in air modulated under differentexternal fields, by altering laser sources and/or photon energy levels,i.e., by using either P405 or P407 to emit laser-beam photons and/orgenerate photon-electron couplings to be a quantum state of throughgradient spinning magnetic fields of 70D, 70D150t, 98D, 101D, 104D,109D, 113D, 117D, RTD10t, RTD50t, and RTD110t in the L₁₆(2)¹⁵ and theL₉(3)⁴ optimum protocols to form convertible symmetry spin-up andspin-down qubit operator networks and non-symmetry spin-up and spin-downqubit operator networks in frequency domains and time domains in a rangeof about ±10⁻¹⁹ Hz/s to about ±10⁻⁷ Hz/s); the bio-electron-photonco-coupling-driven convertible symmetry spin-up and spin-down qubitoperator networks and non-symmetry spin-up and spin-down qubit operatornetworks are one-level and two-level Hadamard- and XOR-gated roomtemperature superconducting qubit networks within ±5000 nm wavelengths;their energy flips of qubit networks in frequency domains and timedomains are in a range of about 5.441E-36_eV to about 109339.95665_eV;their angular momentum of phase transitions in frequency and timedomains are in a range of about 10⁻¹⁹Hz/s to about 10⁵ Hz/s; their phasetransition degrees undergo ±½πN Pauli Z magnetic momentum.
 8. Theprocess of claim 1, wherein the ii) b) and f) measuring step pertainingto -related bio-redox single bioelectron spin-up and spin-downtunneling transportation in a redox nanomedicine quantum dot operatingroom temperature superconducting qubit network is respectively at roomtemperature in air modulated by ±10V bias potentials in the L₁₆(2)¹⁵ andthe L₉(3)⁴ optimum protocols to generate -related convertible symmetryspin-up and spin-down qubit operator networks and non-symmetry spin-upand spin-down qubit operator networks in frequency domains and timedomains; the bio-redox single bioelectron spin-up and spin-downtunneling transportation-driven convertible symmetry spin-up andspin-down qubit operator networks and non-symmetry spin-up and spin-downqubit operator networks are one-level and two-level Hadamard- andXOR-gated room temperature superconducting qubit networks within ±10Vbias potentials; their energy flips of qubit networks in frequencydomains and time domains are in a range of about 5.441E-36 eV to about631,00065 eV; their phase transitions undergo ±½πN Hadamard and/or PauliZ-gated qubit operator networks.
 9. The process of claim 1, wherein theredox nanomedicine quantum dot operating room temperaturesuperconducting qubit networks provides a room temperature in airanalysis method for characterizing a -related one-level and two-levelsuperconducting qubit operator processing that satisfies the trillionlevel binary code matrix Hamiltonians of room temperaturesuperconducting qubit networks as follows: Σ{(2^(n)), n=1, 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12 . . . }; Σ{(2^(n)·2^(n)), n=1, 2, 3, 4, 5, 6 . .. }; Σ{(2^(n+1)), n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 . . . };Σ{(2^(2n)·2^(2n)), n=1, 2, 3 . . . }; Σ{(2^(2n+1)·2^(2n+1)), n=1, 2 . .. }; Σ{(2^(2n+1)), n=1, 2, 3, 4, 5 . . . }.
 10. The process of claim 1,wherein the ii) a) to b), d) and f) measuring step pertaining to-related single bio-electron spins- and/or single bio-photoelectronco-tunneling-driven room temperature superconducting qubit networkscomprises a room temperature in air experimental and analysis method forcharacterizing the redox nanomedicine quantum dot operating roomtemperature superconducting qubit networks; and the ii) b), d) and f)measuring step pertaining to the single bio-electron spin-up andspin-down state may confer a feature of ±½πN phase transition degreesfor one-level and two-level qubit operator networks and theirpermutations at room temperature in air.
 11. The process of claim 1,wherein the ii) c) measuring step pertaining to the bi-stable spin-downand spin-up quantum resonance transport feature of redox nanomedicinequantum dot operating room temperature superconducting qubit networksprovides a room temperature in air method of characterizing ultra-thinand/or ultra-small high performance quantum calculation devices.
 12. Theprocess of claim 1, wherein the ii) a) measuring step pertaining tostructure feature of redox nanomedicine quantum dot networks by theC-AFM image provides a room temperature in air method of imaging 2D˜3Darchitectures of redox nanomedicine quantum dot room operatingtemperature superconducting qubit networks at a nanometer scale.
 13. Theprocess of claim 1, wherein the ii) a) to f) measuring step pertainingto structure-function relationship redox nanomedicine quantum dotnetworks operating qubits by both the C-AFM topographic structure imagesand micro-PL spectra provides a room temperature in air method of qubitmetrology (a -related measurement method standard of qubits), which maycomprise QCVs, namely, average PL spectra, their FFTs, the 1^(st)derivative of relative phases and FFTs in frequency domains and timedomains (dr/df & dr/dt, and dr/df & dr/dt), wherein either dr/df ordr/dt equal to ΔE/.
 14. The process of claim 1, wherein the ii) b) toc) measuring step pertaining to the superconducting feature of redoxnanomedicine quantum dot networks by the C-AFM I-V curve and the 1^(st)derivative of the C-AFM I-V curve provides a room temperature in airmethod of discovering superconductivity (zero conductance at the zerobias potential) and electron-hysteresis peaks within an averagedifference conductance spectrum and its FFT.
 15. The process of claim 1,wherein the ii) a) to f) measuring step pertaining size-controlledstructure dynamic feature of redox nanomedicine quantum dot operatingbio-photoelectron co-tunneling-driven room temperature superconductingqubit networks by the C-AFM images, the C-AFM I-V curve, and themicro-PL spectrum provides a room temperature in air method of qubitmetrology (-related measurement method standard of qubits), namely,complex measurements and analyses of double-peaked average I-V curves,double-peaked average differential conductance spectra and double-peakedaverage laser micro-PL spectra, their FFTs, the 1^(st) derivative ofrelative phases and FFTs in frequency domains and time domains (dr/df &dr/dt and dr/df & dr/dt), wherein either dr/df or dr/dt equals to ΔE/.16. The process of claim 1, wherein the ii) f) measuring step pertainingto a -related measurement method standard of qubits comprises thereproducible measurements of C-AFM I-V curves and micro-PL spectra toacquire an average I-V curve and an average micro-PL spectrum with s.d.,as well as QCVs of redox nanomedicine quantum dot operating roomtemperature superconducting qubit networks at room temperature in air.17. The process of claim 1, wherein the ii) a) to f) measuring steppertaining to -related redox nanomedicine quantum dot operating roomtemperature superconducting qubit networks provides a room temperaturein air experiment-based analytical method of characterizingarchitectures and their photoelectrical properties that includes C-AFMimages, C-AFM I-V curves and FFT, and laser-micro-PL spectra as well as-related QCVs, i.e., their 1^(st) derivatives of relative phase andFFTs for acquiring dr/df=ΔE/ and dr/dt=ΔE/.
 18. The process of claim1, wherein the ii) a) to f) measuring step provides room temperature inair characterizing methods that are used as room temperature in airnano-metrology of QCVs pertaining to qubit processing.
 19. The processof claim 1, wherein the i) preparing step and the ii) measuring steppertain to discovering redox nanomedicine quantum dot operating roomtemperature qubit networks that are prepared and measured by using theprocess of claim
 1. 20. The process of claim 1, wherein the i) preparingstep and the ii) measuring step are networked and used for providingclaim 19 which are used as a central part of bio-photoelectron sensors,advanced information materials, single bioelectronics transistors,implanting nano-bio-photoelectron sensors, newly medical diagnostictools like room temperature superconductivity nuclear magnetic imaging,cardio-cerebral magnetic probing, high performance single bioelectronand single bio-photon co-tunneling-driven room temperaturesuperconductivity qubit informatics and nanometer photoelectronbiosensors, and key technology employed in communication, traffic andnational defense advanced tools like quantum computers,superconductivity magnetic body, energy storage systems, or standardreference samples.